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CHAPTER I 
 
INTRODUCTION 
 
The Obesity Pandemic 
 Obesity is a pandemic affecting developed and developing countries. Current 
reports show that over 33% of adults in the United States are obese (defined as 
having a body mass index [BMI] ≥ 30.0 kg/m2) (1). A Center for Disease Control 
publication reports that people who are obese incurred $1,429 more in medical 
costs per year than people of normal weight, making the nation’s total medical 
cost of obesity $147 billion in the year 2008 alone (2).  Even more concerning, 
the prevalence of obesity is on the rise in children and adolescents. The 
percentage of obese children and adolescents tripled in the United States from 
1980 to 2008 (3). This is alarming because studies have shown that children and 
adolescents that are obese have an 80% greater likelihood of being overweight 
or obese as adults (4). 
 Obesity is a complex disease that involves both genetic and environmental 
factors (1), with the exception of some rare single gene mutations (5, 6). Obesity 
increases the risk of mortality by all causes, and people with a BMI higher than 
35 have a significantly greater risk of dying from a wide range of diseases (Figure 
1.1) (7). Several health problems are associated with obesity, including sleep 
apnea, osteoarthritis, hypertension, cancer, dyslipidemia, insulin resistance (IR), 
type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD) (4). In fact, 
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the relative risk for the latter four is over threefold higher in obese compared to 
lean individuals.  
 
Insulin Resistance and Type 2 Diabetes 
 Obesity significantly raises the risk for developing T2DM (4). According to 
Center for Disease Control statistics, approximately 1 out of 9 adults in the 
United States are diabetic, and 1 out of 3 adults are pre-diabetic, a state also 
known as IR. In general, people with T2DM have a life span that is 5 to 10 years 
shorter than people without this disease. The most common long-term effect of 
T2DM is damage to the cardiovascular system, which includes macrovascular 
complications (atherosclerosis and amputations) and microvascular 
complications (retinopathy, nephropathy, and neuropathy) (8). 
 During the insulin resistant pre-diabetic stage, there is a reduction in insulin-
stimulated glucose uptake; however, the pancreatic islets respond to this state by 
enhancing their mass and insulin secretion. After a certain period of IR, the 
expansion and increased secretory activity of β-cells fails to compensate for the 
increasing degree of IR, a state known as β-cell failure, which corresponds to the 
onset of T2DM (9).  The leading mechanisms for IR and β-cell failure include 
oxidative stress, endoplasmic reticulum stress (ER stress), ectopic lipid storage 
in the muscle, liver and pancreas, lipotoxicity and glucotoxicity. These 
mechanisms are also associated with obesity and AT inflammation (10, 11), as 
described below. 
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Insulin Signaling 
 In order to understand the molecular mechanism of IR, it is imperative to first 
define the insulin signaling pathway. Insulin signals through its tyrosine kinase 
insulin receptor (INSR). After INSR autophosphorylation, this receptor catalyzes 
the tyrosine phosphorylation of the insulin receptor substrates (IRS-1, -2). 
Tyrosine phosphorylated IRS then binds to the Src-homology (SH)-2 site of the 
regulatory domain of phosphatidylinositol 3-kinase (PI3K). This leads to the 
activation of the catalytic subunit of PI3K, which catalyzes the production of the 
second messenger PIP3. PIP3 binds 3-phophoinositide-dependent protein 
kinase-1 (PDK-1), which phosphorylates and activates AKT, also known as PKB. 
This serine/threonine kinase mediates the activation/inactivation of many 
downstream mediators including FOXO1 and small GTPases. FOXO1 mediates 
transcriptional regulation and small GTPases lead to the translocation of the 
insulin sensitive glucose transporter-4 to the cell membrane, leading to 
transporter-mediated glucose uptake (12) (Figure 1.2). 
 
Mechanisms of Insulin Resistance 
  AT inflammation during obesity is a key event that leads to the production of 
inflammatory mediators that have been shown to promote IR. These 
inflammatory factors include free fatty acids and cytokines. Signaling 
downstream of cytokines and free fatty acids through cytokine receptors or toll-
like receptors, respectively, lead to the activation of serine kinases such as JUN 
N-terminal kinase (JNK) and IKB Kinase (IKK). These kinases catalyze the serine 
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phosphorylation of IRS’s, making them less sensitive to tyrosine phosphorylation, 
thus, decreasing insulin signaling (13). In addition, signaling downstream of 
cytokines such as interleukin 6 (IL-6) can lead to the activation of suppressors of 
cytokine signaling (SOCS), which can block the interactions between the INSR 
and IRS (14) (Figure 1.2). Many of the inflammatory mediators produced in AT 
during obesity are discussed in detail below. 
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Figure 1.1 Risk of mortality in both men and women increases with 
increases in body mass index. Adapted from Bray et al. West J Med 1988; 
149:429-41(7). 
 
Figure 1.2 Insulin Signaling and Insulin Resistance Pathways. From 
Kalupahana et al. Mol Aspects of Medicine 33 (2012) 26-34 (15). 
  
6 
 
Adipose Tissue as an Endocrine Organ 
AT consists of two fractions, the adipocyte fraction where most fat storage 
occurs, and the stromal vascular fraction (SVF), which contains endothelial cells, 
fibroblasts, and several immune cell types. All the different cell types contribute 
to the secretion of hormones, cytokines and adipokines that act in other tissues 
directly involved in systemic glucose metabolism such as the liver and muscle, 
and centrally in the brain. The most studied adipokine to this date is leptin (16, 
17); the circulating levels of this adipokine have a strong association with obesity 
and its associated co-morbidities.  
Additionally, the secretion of several other inflammatory AT factors is 
increased with obesity; these include tumor necrosis factor –α (TNF-α), resistin, 
IL-6, IL-1β and monocyte chemoattractant protein 1 (MCP-1). The factors 
secreted by AT during obesity that are relevant to this dissertation are shown in 
Figure 1.3. There is a strong temporal correlation between the infiltration of 
macrophages into AT and onset of IR in this tissue (18, 19). Additionally, 
macrophage infiltration into AT is correlated with AT dysfunction and subsequent 
onset of IR in the liver and muscle possibly due to ectopic lipid accumulation and 
increased inflammation.  
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Figure 1.3 Hormones, Cytokines and Adipokines Produced in AT. From 
Trayhurn et al. (20). 
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Adipose Tissue Inflammation 
 A large part of this section on AT inflammation was published in my review 
for Current Diabetes Reports (21). Early studies on obesity showed that there 
was increased expression of the inflammatory mediator TNF-α in the AT of obese 
humans and rodents when compared to their lean counterparts (18, 22, 23).  
Studies published a decade later clearly demonstrated that the presence of 
macrophages in AT increases in obesity and that most of the production of 
inflammatory factors was mediated by the immune cells in the SVF, mainly the 
macrophages (19, 24). Since discovering a link between obesity and increased 
AT macrophages (ATMs), different genetic and diet-induced obese mouse 
models have been used to study the nature of AT inflammation. Importantly, 
much focus has been placed on investigating the factors that lead to the 
increased accumulation of ATMs in obese AT (25).  
 
Mechanisms of macrophage recruitment to AT 
 Extensive research has been performed to understand the factors that initiate 
macrophage infiltration into AT. Many possible AT-specific cells and molecules 
can contribute to the macrophage infiltration of AT, including apoptosis of 
adipocytes due to hypoxia and increased production of chemokines. 
 
Adipocyte apoptosis 
 During AT expansion, hypoxia can occur due to reduced delivery of oxygen 
to the hypertrophic adipocytes (26). This hypoxia can cause an increase in 
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inflammatory cytokine production from adipocytes and can also lead to adipocyte 
cell death (27). As a part of their natural role in innate immunity, macrophages 
can be attracted to AT to phagocytose these dead adipocytes. Cinti et al. (28) 
and Strissel et al. (29) used electron microscopy and immunohistochemical 
techniques to show that the macrophages in AT are often localized to crown-like 
structures surrounding adipocytes that are believed to be dead or dying. These 
adipocytes are thought to have increased inflammatory cytokine and chemokine 
secretion that may also contribute to further macrophage recruitment, as 
described below. 
 
Chemokines 
 Several groups have reported that macrophage chemokines are upregulated 
in AT during obesity (30-32). Furthermore, our laboratory has shown that 
Western diet-fed Agouti yellow mice have a dramatic increase in MCP-1 and 
MIP-1α expression in AT compared with lean controls (33). Increased chemokine 
expression in obese AT is also found in humans. A study by Huber et al. (34) 
found an increase in the expression of MCP-1 and its receptor, CCR2, in AT of 
obese patients (BMI, 53.1 kg/m2) when compared with AT of individuals with an 
average BMI of 25.9 kg/m2. They also found that expression of two different 
chemokines, CCL3 (MIP-1α) and CCL5 (RANTES) positively correlated with 
fasting plasma insulin levels in obese individuals. 
Evidence also exists that manipulating the chemokine system can alter ATM 
accumulation. Weisberg et al. (35) found that obese mice lacking CCR2 had 
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reduced macrophage recruitment, decreased proinflammatory gene expression, 
and improved insulin sensitivity when compared with obese wild-type mice after 
long periods of HFD feeding. Kanda et al. (30) tested three different conditions: 
overexpression of MCP-1 in AT, global disruption of the MCP-1 gene, and 
expression of a dominant-negative MCP-1 mutant. Their results showed that 
MCP-1 overexpression increased macrophage infiltration and promoted IR, 
whereas silencing of the MCP-1 gene or expression of a dominant-negative 
mutant reduced ATM recruitment and improved insulin sensitivity. Together, 
these data would suggest that chemokine expression in AT plays an important 
role in macrophage recruitment to AT; however, since the publications of these 
studies several conflicting findings have been made, including the studies 
described in Chapter III and IV of this dissertation (36, 37).  
 
In addition, other groups have demonstrated that deficiency of these and 
other chemokines and their receptors does not affect macrophage accumulation 
in AT (32, 38-41). These opposing findings suggest that the role of MCP-1 and 
other chemokines in macrophage recruitment to AT is complex and that many 
other factors may contribute to this process, including macrophage turnover as 
described in Chapter VI of this dissertation. Alternatively, these findings suggest 
that active chemokine-mediated macrophage recruitment to AT may not be an 
important factor in their accumulation in this tissue. 
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When this dissertation work was initiated there was much interest in the 
potentially key role of leptin in macrophage recruitment to AT (21, 42). Our 
laboratory had shown that leptin was a potent monocyte chemoattractant in vitro 
(43). Additionally, Curat et al. had demonstrated that leptin was important in the 
diapedesis of monocytes into AT. Both of these studies led to the speculation 
that leptin could be an important player in macrophage recruitment to AT in vivo. 
In fact, several review papers were written highlighting the importance of leptin in 
this process (21, 44, 45). Chapter III of this document investigated this 
hypothesis in vivo and it is the seminal project of this dissertation. 
 
Adipose Tissue Macrophage Phenotype 
 ATMs have been classified into two simplified primary phenotypes: M1 
“classically activated” and M2 “alternatively activated.” In vitro, M1 macrophages 
are polarized and activated in response to stimulation by bacterial 
lipopolysaccharide and by interferon-γ. These cells have a “pro-inflammatory” 
phenotype, specialized in fighting bacterial infections. Conversely, M2 
macrophages have been defined in vitro, as cells stimulated with the Th2 
cytokines IL-4 and/or IL-13, and are characterized by the increased expression of 
arginase-1, IL-10 and mannose receptor. M2 macrophages have a predominantly 
anti-inflammatory phenotype (46). 
 
Lumeng et al. (47, 48) were among the first to propose a differential 
activation of ATMs depending on the degree of adiposity. They found that ATMs 
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from lean and CCR2-/- obese mice express many genes characteristic of M2 
macrophages, including Ym1, arginase 1, and IL-10. Studies by Wu et al. and my 
own work  described in Chapter IV of this dissertation, have shown that the 
prevalence of an M2 phenotype in the macrophages of CCR2-/- mice is likely due 
to the increased number of eosinophils that secrete the TH2 cytokine IL-4 in this 
tissue (49).   
 
Conversely, diet-induced obesity in wild-type mice decreased the expression 
of M2 genes and increased the expression of pro-inflammatory M1 genes, such 
as TNF-α, IL-6, and inducible nitric oxide synthase (iNOS). Thus, diet-induced 
obesity leads to a shift in macrophage phenotype from an anti-inflammatory M2 
type to a pro-inflammatory M1 type, and CCR2 appears to play an important role 
in this phenotypic switch ((50) and Chapter IV of this dissertation).  
 
The role of M1 versus M2 ATMs in controlling inflammation and IR in AT has 
been delineated by recent studies demonstrating that peroxisome proliferator-
activated receptor (PPAR)-γ and PPAR-δ are integral for induction of M2 
macrophages. First, an increase in M2 markers is induced upon the activation of 
PPAR-γ with rosiglitazone (51). Second, macrophage deficiency of PPAR-γ or 
PPAR-δ results in a reduction of M2 macrophages in the AT, leading to an 
increase in IR, possibly due to the reduced presence of protective M2 
macrophages (52, 53). Taken together, these results indicate that a higher 
degree of adiposity is positively correlated with increased numbers of M1 
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macrophages and a heightened state of inflammation and IR. Whereas a lower 
degree of adiposity is strongly correlated with an increased number of M2 
macrophages and dampened inflammation leading to improved insulin sensitivity. 
 
Other Immune Cells in AT 
 Since the initial discovery of the infiltration of macrophages into AT, several 
other immune cells have been shown to play a role in AT inflammation, including 
CD8+ T cells, CD4+ TH1, TH2 and TH17 cells, CD4
+CD25+FOXP3+ regulatory T 
cells, NKT cells, neutrophils, mast cells, B cells and eosinophils (Reviewed in 
(54, 55)). All of these cell types and their roles have become important in paving 
the road to understanding the regulation of AT function and inflammation in lean 
and obese humans and rodents.  A comprehensive analysis of the effects of 
these cells on AT function is provided below and summarized in Table 1.1 and 
Figure 1.4 at the end of this section. 
 
 CD8+ T cells 
 CD8+ effector T cells have been shown to infiltrate AT during obesity. These 
cells play an important role in promoting AT inflammation and systemic IR (56-
58). Two studies have shown that infiltration of AT by CD8+ T cells precedes the 
infiltration of macrophages, and that in fact these cells are important contributors 
to macrophage recruitment into AT. Ablation of CD8+ T cells led to decreased 
levels of macrophages in AT and improved insulin sensitivity. Conversely, 
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adoptive transfer experiments of CD8+ T cells into wild-type mice led to increased 
AT inflammation and worsened IR (56, 57) (Table 1.1 & Figure 1.4). 
 
 CD4+ TH1, TH2 and TH17 Cells 
 Interferon-gamma (IFN-γ) producing CD4+ TH1 cells have been shown to be 
increased in AT during obesity and ablation of these cells has been shown to 
improve AT inflammation and decrease IR (56-59). Similarly, obesity leads to the 
expansion of the pools of TH17 T cells in AT, promoting inflammation (60). In 
contrast, CD4+ TH2 cells have been shown to be decreased with the progression 
of obesity, and adaptive transfer of these cells leads to improvements in 
inflammation and IR (59, 61) (Table 1.1 & Figure 1.4). 
 
CD4+CD25+FOXP3+ Tregs 
 T regulatory cells are important players in controlling autoimmunity, allergic 
responses, inflammation and other types of immune responses (55). They 
usually make up about 5-20% of the CD4+ T cell population (62). Importantly, 
these cells have been shown to be one of the key regulators of inflammation in 
AT, as they have the power to control the immune response regulated by all cells 
of the innate and adaptive immune system (63). Tregs are a major source of IL-10 
in lean AT. Levels of Tregs have been found to be higher in lean mice and humans 
and the percentage of these cells are decreased with weight gain (56, 59, 63). 
Selective ablation of AT Tregs leads to increased inflammation and worsened IR 
(61, 63) (Table 1.1 & Figure 1.4). 
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 B cells, Mast cells and NKT cells 
 B cells, mast cells and NKT cells have all been shown to be increased in AT 
during obesity. Furthermore, their increased numbers are known to promote AT 
inflammation and systemic IR. Conversely, the selective ablation of these cells 
leads to decreased inflammation and improved insulin sensitivity (64-66) (Table 
1.1 & Figure 1.4). 
 
 Eosinophils 
 Eosinophils are the newest player added to the milieu of immune cells in the 
AT. Eosinophils, similar to “M2” polarized macrophages, have traditionally been 
known to play an important role in host protection against parasites. However, 
recently these cells have been shown to play important roles in asthma, allergy 
and the regulation of the innate and adaptive immune system (67). Studies by 
Wu et al. have made important contributions to understanding the role of 
eosinophils in AT inflammation and the systemic metabolic effects, as well as 
their regulation with respect to HFD (49). Eosinophils have been found to support 
the alternative activation of macrophages in AT by producing and secreting IL4; 
therefore, their ablation leads to increased inflammation and worsened IR. 
Additionally, just like other anti-inflammatory cells in AT, their numbers decrease 
with increasing adiposity (49) (Table 1.1 & Figure 1.4). Chapter IV of this 
dissertation describes the discovery of increased numbers of eosinophils in the 
AT of CCR2-/- mice. Additionally, these data made important contributions to 
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understanding the regulation of eosinophils in AT during obesity (discussed in 
detail in Chapter IV). 
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Figure 1.4 Adipose Tissue Immune Cells.  From Winer et al. Immunology and 
Cell Biology 2012: 1-8 (54). Obesity leads to a macrophage phenotypic switch 
from M2 to M1. Additionally obesity leads to a decrease in the anti-inflammatory: 
eosinophils, TH2 CD4+ T cells and regulatory T cells. In contrast, the levels of B 
cells, mast cells, CD8+ T cells, NK cells  and TH1 CD4+ T cells are increased 
with obesity.  
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Table 1.1 Immune cells in Adipose Tissue 
Cell Type Inflammation Obesity Effect Citation 
“M1” Macrophages ↑ ↑ (19, 24, 47, 50) 
“M2” Macrophages ↓ ↓ (47, 50) 
CD8+ T cells ↑ ↑ (56, 57) 
CD4+ TH1 Cells ↑ ↑ (58, 59) 
CD4+ TH2 Cells ↓ ↓ (57-59) 
CD4+ TH17 Cells ↑ ↑ (60) 
CD4+CD25+FOXP3+ 
TRegs 
↓ ↓ (56, 59, 63) 
B Cells ↑ ↑ (64) 
NKT Cells ↑ ↑ (66) 
Mast Cells ↑ ↑ (65) 
Eosinophils ↓ ↓ (49) 
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Molecules Studied in This Dissertation 
This dissertation investigated the effects of deficiency of the leptin 
receptor, CCR2 and complement 5 on AT inflammation and Immunometabolism. 
The first goal of this dissertation was to test whether leptin was an important 
macrophage chemoattractant in vitro and in vivo. Chapter III provides a detailed 
analysis of the results obtained from this project. While performing the in vivo 
portion of project 1, CCR2 deficient mice were used as a positive control, which 
led to the discovery of a previously unknown immune cell population in the AT of 
the mice deficient for this receptor. The results from these studies are presented 
in Chapter IV. In the process of performing the in vitro section of project 1, 
complement factor 5a (C5a) was used as a positive control for macrophage 
migration studies. The results obtained led to the generation of the hypothesis for 
project 3; the findings from this project are presented in Chapter V of this 
dissertation. 
 
Leptin and Leptin Receptor 
Leptin is a 16 kDa soluble protein encoded by the Ob gene and is 
expressed primarily by white AT (16, 33). In lean humans, total plasma leptin 
concentrations average 1.6-16 ng/ml (68). Obese individuals are known for 
having central leptin resistance and increased circulating levels of leptin due to 
the expansion of white AT (69). The circulating plasma levels of leptin for obese 
humans have been shown to be > 80 ng/ml (68). 
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  Leptin acts through the long form of the leptin receptor (LepR) and plays an 
important role in weight regulation through its action in the hypothalamus (70). 
The LepR belongs to the IL-6 class I family of cytokine receptors. LepR does not 
contain intrinsic enzymatic activity, but instead signals through its non-covalent 
association with the tyrosine kinase, Janus Kinase 2 (JAK2).  The activation by 
tyrosine phosphorylation of LepR triggers several tyrosine kinase signaling 
cascades that carry out multiple cellular functions (71). Mice that lack either leptin 
or the LepR are characterized by severe hyperphagia and morbid obesity, as well 
as other hormonal abnormalities (72).  
  
 Our laboratory showed that leptin is a potent monocyte chemoattractant, and 
that LepR signaling is required for this chemotaxis in vitro (43). Given that leptin 
is primarily secreted from AT and that its circulating levels are positively 
correlated with increases in macrophage infiltration (33), we hypothesized that 
leptin could act as a monocyte chemoattractant that regulates macrophage 
recruitment to AT in vivo.  In Chapter III of this dissertation I tested this 
hypothesis and found that LepR deficiency does not affect macrophage 
recruitment to AT. 
 
 CC-Chemokine Receptor 2 
CCR2 is the functional receptor for the chemokines CCL2 (MCP-1), CCL7 
and CCL8 (35). CCR2 is expressed in myeloid, lymphoid and stromal cells (73). 
CCR2-/- mice were found to have an immune deficiency in Th1 responses 
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characterized by low levels of IFNγ production and delayed macrophage 
recruitment to sites of inflammation (74).  Since that initial study, CCR2-/- mice 
have been shown to have reduced recruitment of monocytes in several 
inflammatory disease models including auto immune encephalitis (75), peritonitis 
(74), atherosclerosis (76) and tuberculosis (77). In Chapter IV of this dissertation, 
I show that CCR2 not only plays an important role in monocyte/macrophage 
migration to AT; its deficiency leads to the accumulation of eosinophils in this 
tissue, which has a large impact on systemic insulin sensitivity. 
 
Complement Factor 5 
             The complement system is a vital component of innate and adaptive 
immune responses and is conserved across a wide range of species. Three 
different complement activation pathways have been discovered: the classical, 
alternative, and lectin binding pathways. The classical pathway is activated by 
antigen-antibody complexes. The alternative pathway is initiated by surface 
molecules containing carbohydrates or lipids. The lectin-binding pathway is 
activated by the binding of mannose-binding lectin protein (58) to bacterial 
carbohydrate structures. In the alternative pathway, circulating complement 3 is 
continuously hydrolyzed to C3-H2O.  C3-H2O binds to factor B (FB) to form C3-
H2OB, which can be cleaved by factor D to form C3 convertase (C3-H2OBb), 
resulting in cleavage of C3 to C3a and C3b. C3b binds factor B to form C3bB and 
form the alternative pathway’s C5 convertase, C3b3bBb, which cleaves 
complement 5 into C5a and C5b (61) (Figure 1.5); the known functions of both of 
these clevage products are described in detail below. The role of complement in 
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the immune response has been recognized since the early 1900’s; however its 
role in AT biology is just beginning to be elucidated. In the early 1990’s, the 
discovery that a product of the C3a anaphylatoxin (C3a des-Arg or acetylation 
stimulating protein) allegedly induced triglyceride synthesis and accumulation in 
adipocytes, has led several investigators to study the role of this system in AT 
physiology (78-80). This prompted the discovery of the expression of other 
proteins involved in the alternative activation pathway in AT, including C3, Factor 
B and Adipsin (factorD) (78), suggesting that this pathway is active in AT.  High 
expression of complement components has also been shown in the omental AT 
of obese humans (81).    
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Figure 1.5 Alternative Complement Activation Pathway. Adapted from Guo, 
R. F.  et al. Annu. Rev, Immunol.  2005 (61). 
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  C5a  
C5a has recently been implicated in the pathogenesis of several 
inflammatory diseases, including sepsis (61), rheumatoid arthritis (82), ischemia-
reperfusion injury and atherosclerosis (83). C5a is a pleitropic peptide and the 
most potent anaphylatoxin of the complement cascade. It has many functions in 
the immune system: it is a strong chemoattractant for all cells of the myeloid 
lineage and some cells of the lymphoid lineage (84), it has been shown to be 
involved in the modulation of cytokine expression in different cell types (85), and 
it upregulates adhesion molecules in neutrophils, monocytes and epithelial cells 
(86).  
C5b 
C5b is the seminal component of the membrane attack complex (MAC or 
C5b-9), which also consists of C6, C7, C8 and C9. The MAC inserts into the 
membrane of target cells directly inducing cell lysis and necrosis (87). Sublethal 
amounts of C5b-9 activate immune cells and endothelium by upregulating 
adhesion molecules and promoting the release of reactive oxygen species, 
arachidonic acid metabolites and cytokines (83, 88, 89). The C5b-9 complex has 
been shown to play an important role in many diseases, including renal-
reperfusion injury (83) and partial lipodystrophy (90).   
This project was designed to study the role of complement factor 5 in AT 
inflammation and systemic IR. In Chapter V of this dissertation, I show that C5 
deficiency leads to severe systemic IR in mice, this IR is inflammation 
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independent, and it is due to reduced insulin receptor message and protein 
expression.  
 
Significance 
Obesity is closely linked to many metabolic diseases such as IR, T2DM, 
and cardiovascular disease (91). In the past decade, it has been established that 
immune cells are recruited to AT triggering an inflammatory response 
characterized by abnormal cytokine production and activation of inflammatory 
signaling pathways that are temporally associated with IR (19, 24). Nonetheless, 
there is a gap in our understanding of what triggers and regulates this 
inflammatory response. Consequently, there are no effective treatments to 
ameliorate the pathogenesis of this disease. This dissertation covered several 
aspects involved with AT dysfunction, inflammation and IR during obesity. This 
work has contributed to the field of Immunometabolism by investigating LepR, 
CCR2 and C5 deficiency in vivo. The studies performed in this dissertation led to 
the identification of specific roles for all these molecules in either macrophage 
recruitment to AT, macrophage polarization, regulation of other immune cells in 
AT, and inflammation-independent regulation of glucose metabolism. 
  
26 
 
CHAPTER II 
 
MATERIALS AND METHODS 
 
Mice and Diets 
All animal care and experimental procedures were performed with 
approval from the Institutional Animal Care and Use Committee of Vanderbilt 
University. All studies were performed with 8 week old male mice. In addition, in 
all studies mice were fed ad libitum and given free access to water. 
 
Chapter III: The LepR+/+, LepR-/- and CCR2-/- mice were purchased from Jackson 
Laboratories (Bar Harbor, Maine) and were on a C57BL/6 background. DKO 
(LepR-/-; CCR2-/-) donor mice were generated by crossing CCR2-/- with LepR+/- 
mice.  Mice were kept on antibiotic water for 1 week prior to bone marrow 
transplant (BMT) until 4 weeks post-BMT. Mice were then placed on a 60% fat 
diet from Research Diets, Inc. (D12492) with a caloric density of 5.24 kcal/g; 
starting at 4 weeks post-BMT for a total of 6 or 12 weeks (Figure 2.1).  
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Figure 2.1 Chapter III Study Design. 
C57BL/6 mice were transplanted with either LepR+/+, LepR-/- or DKO (LepR-/-; 
CCR2-/-) bone marrow at 8 weeks of age. After 4 weeks mice were placed on a 
60% diet (HFD) for 6 or 12 weeks (n = 10 per group). GTTs and ITTs were 
performed after 6 and 12 weeks. Mice were sacrificed after the 6 or 12 week 
period for analysis of AT macrophage infiltration and inflammation. 
 
 
Chapter IV: The CCR2-/- and CCR2+/+ mice used for this study were originally 
purchased from Jackson Laboratories, are on a C57BL/6 background, and have 
been propagated in our animal facility. In the BMT study mice were kept on 
antibiotic water from 1 week prior to BMT through 4 weeks post-BMT. BMT and 
non-BMT mice were then placed on a 60% fat diet from (Research Diets, Inc., 
New Brunswick, NJ) for varying periods of time.  
 
Chapter V: C57BL/6, B10.D2-Hc0 H2d H2-T18c/oSnJ (C5 deficient and referred 
to as C5D in this dissertation), C57BL/10SnJ (WT controls H2b haplotype), and 
B10.D2-Hc1H2d H2-T18c/oSnJ (WT controls H2d haplotype) mice were purchased 
from The Jackson Laboratory (Bar Harbor, Maine). Eight-week-old C57BL/6 mice 
were placed on a 10%, 45% or 60% fat diet (Research Diets, Inc., New 
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Brunswick, NJ) for 16 weeks. C5D and WT mice were placed on either a 10% or 
60% fat diet for 12 weeks. 
 
Bone Marrow Transplantation 
Chapter III: Bone marrow cells were collected from LepR+/+, LepR-/- and DKO 
(LepR-/-; CCR2-/-) donor mice and were injected into the retro-orbital venous 
plexus of lethally irradiated recipient WT mice. Complete reconstitution of the 
desired bone marrow was confirmed by PCR of splenic cells using primers 
specific for the db allele (forward primer: 5’-AGA ACG GAC ACT CTT TGA AGT 
CTC-3’; reverse WT: 5’-AAC CAT AGT TTA GGT TTG TTT C-3’; reverse db: 5’-
CAA TTC AGT GTA AAC CAT AGT TTA GGT TTG TTT A-3’). This generates a 
band of 129 base-pairs for the WT allele and 141 base-pairs for the db allele 
(Figure 2.2) 
Chapter IV: Bone marrow cells were collected from CCR2+/+ or CCR2-/- donor 
mice and were injected into the retro-orbital venous plexus of lethally irradiated 
recipient CCR2+/+ mice as previously described (92). The efficiency of bone 
marrow reconstitution was confirmed by PCR using DNA isolated from the 
spleens of the recipient mice using primers specific for the Neo cassette insertion 
(forward primer: 5’-CTT GGG TGG AGA GGC TAT TC-3’; reverse primer: AGG 
5’-TGA GAT GAC AGG AGA TC-3’) in the CCR2-/- deficient mice (Figure 2.3). 
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Figure 2.2 Genotyping of splenocytes from BM-LepR+/+ and BM-LepR-/- 
mice.  
Confirmation of the reconstitution of the desired bone marrow was performed by 
isolating DNA from splenocytes of the recipient mice at the end of the study. The 
129 base-pair band corresponds to the amplification of the wild-type allele. The 
141 base-pair band corresponds to the amplification of the db allele. 
Representative blot, WT: wild-type control DNA; db: db/db control DNA.  
 
Figure 2.3 Genotyping of splenocytes from BM-CCR2+/+ and BM-CCR2-/- 
mice.  
The confirmation of the reconstitution of the desired bone marrow was performed 
by isolating DNA from splenocytes of the recipient mice at the end of the study. 
Band corresponds to Neo cassette amplification. CCR2-/- mice have a targeted 
insertion of the Neo gene. Representative blot; WT: wild-type (CCR2+/+) control 
DNA; CCR2-/- control DNA. 
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Body weight, Body Composition and Food Intake.  
In all studies, body weight and food intake were measured weekly for the 
duration of the study. Total lean, fat, and free fluid mass were measured by 
nuclear magnetic resonance (NMR) using a Bruker Minispec (Woodlands Texas) 
in the Vanderbilt Mouse Metabolic Phenotyping Center (MMPC) at baseline, 6 
and 12 weeks after placement on either a LFD or HFD. 
 
Insulin and Glucose Tolerance Tests.  
Mice were fasted for 5 h and baseline glucose levels were measured 
using a LifeScan One Touch Ultra glucometer (Johnson & Johnson, Northridge, 
CA) via the tail vein.  
Chapter III & IV: Mice were injected intraperitoneally with either 0.4 U (6 weeks 
of HFD) and 0.5 U (12 weeks of HFD) insulin per Kg of lean mass; or 2 g (6 
weeks of HFD) and 1 g (12 weeks of HFD) dextrose per kg of lean mass. 
Glucose levels were then assessed at 15, 30, 45, 60, 90 and 150 min post-
injection.  
Chapter V: Mice were then injected with 1g of glucose per kg of lean body mass. 
Glucose levels were assessed at 15, 30, 45, 60, 90, 120 and 150 min after 
glucose injection. 
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Plasma Collection and Measurements  
In all studies mice were fasted for 5 h and bled from the retro-orbital 
venous plexus using heparinized collection tubes. Plasma was separated by 
centrifugation and stored at -80 ºC. Plasma insulin levels were measured using 
an ELISA kit from Millipore, Inc (Billerica, MA). Leptin levels were assessed at 
the Vanderbilt University Hormone Core.  
 
Real-time RT-PCR   
In all studies, RNA extraction was performed with an RNeasy kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions. The iScript cDNA 
synthesis kit (BioRad, Hercules, CA) was used for reverse transcriptase 
reactions. Real-time RT-PCR experiments were performed using an iQ5 thermal 
cycler.  The reactions were carried out using IQ Supermix (BioRad) and FAM 
conjugated Assay-on-Demand (Applied Biosystems, Foster City, California) 
primer/probe sets normalized to 18S or Gapdh.  
 
Chapter III: The following genes were assessed: 18S (4352930E), Emr1 
(Mm00802530_m1), Arg1 (Mm01190441_g1), Cd68 (Mm00839636_g1), Tnf 
(Mm00443258_m1), Nos2 (Mm00440502_m1), Cd163 (Mm0118511), Mgl1 
(Mm00546125_g1), Mgl2 (Mm00460844_m1), Il6 (Mm00446190_m1), and Il1b 
(Mm9999061_mH). Data were presented as expression relative to the BM-
LepR+/+ controls at each respective time point.  
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Chapter IV: The following genes were assessed: Gapdh (Mm99999915_g1), 
Emr1 (Mm00802530_m1), Arg1 (Mm01190441_g1), Cd68 (Mm00839636_g1), 
Tnf (Mm00443258_m1), Nos2 (Mm00440502_m1), Itgam (Mm00434455_m1), 
Itgax (Mm00498698_m1), Mpo (Mm00447886_m1), Cxcl1 (Mm04207460), Cxcl2 
(Mm00436450_m1), Il8rb (Mm00438258_m1), Ccl2 (Mm004411242), Ccl3 
(Mm00441258), Cd163 (Mm0118511), Mgl1 (Mm00546125_g1), Mgl2 
(Mm00460844_m1), Il10 (Mm00439614_m1), Csf3 (Mm00438354_m1), Ccl5 
(Mm01302428_m1), Il6 (Mm00446190_m1), Mmp9 (Mm00442991_m1), Il1b 
(Mm9999061_mH), Csf1 (Mm00432686_,1) and Csf1r (Mm01266652_m1), Il5 
(Mm00439646_m1). Data were presented as expression relative to the BM-
CCR2+/+ or CCR2+/+ controls at each respective time point. 
 
Chapter V: The following genes were assessed: Gapdh (Mm99999915_g1), 
Emr1 (Mm00802530_m1), Arg1 (Mm01190441_g1), Tnf (Mm00443258_m1), 
Nos2 (Mm00440502_m1), Ccl2 (Mm004411242), Il10 (Mm00439614_m1), Il1b 
(Mm9999061_mH), C3ε (Mm00599683_m1), Insr (Mm01211875_m1), Irs1 
(Mm01278327_m1), Hc (Mm00439275_m1), C3 (Mm01232779_m1), C6 
(Mm00489521_m1), Cfb (Mm04333909_m1), Irs2 (Mm03028438_m1), Igfbp3 
(Mm0051515156 _m1), Igf1 (Mm00439560_m1), Igf1r (Mm00802831_m1), G6pc 
(Mm00839363_m1), Pck1 (Mm01247058_m1), Gck (Mm00439129_m1), Acacb 
(Mm01204578_m1), Acox1 (Mm00443579_m1). Data were presented as 
expression relative to the WT 10% fat diet controls at each respective time point. 
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In all studies, the data were analyzed using the Pfaffl method (93) and presented 
as relative expression. 
 
Histology 
  Epididymal AT was harvested from mice, weighed, and a portion was fixed 
overnight in 10% (v/v) formalin, transferred to 70% (v/v) ethanol, and paraffin 
embedded.  
 
Chapter III & IV: Tissue was cut into 7μm sections and stained with 0.1% (w/v) 
toluidine blue O solution (TBO) (Newcomer Supply, Middleton, Wisconsin) as 
previously described (33).  
 
Chapter IV: CD11bloF4/80lo and CD11bhiF4/80hi sorted cells were cytospun onto 
glass slides and stained with hematoxylin and eosin (H&E). 
 
Chapter V: Liver and pancreata samples were collected and frozen in OCT 
solution, and stored at -80 C. AT samples were fixed in 10% formalin overnight 
and paraffin embedded. Seven micrometer sections of liver and AT were cut 
using a cryostat and microtome, respectively. H&E staining was performed as 
previously described. The pancreata were cut and stained by the Vanderbilt 
Histology and Immunohistochemistry Core. 
In all studies, images were captured using an Olympus BX51 microscope 
(Tokyo, Japan).  
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Peritoneal Macrophage Collection 
 Chapter IV: Mice were injected intraperitoneally with 3 ml of 3% 
thioglycollate to induce sterile inflammation. After 3 days, the peritoneal cells 
were collected by lavage with 10 ml of PBS with 0.5% BSA, washed and counted 
before used for flow cytometric analysis.  
 
Stromal Vascular Fraction (SVF) Separation 
Chapter II & IV: Epididymal AT pads were excised and minced in 3 ml of 0.5% 
(w/v) BSA in PBS and placed on ice.  Subsequently, 3 ml of 2 mg/ml collagenase 
was added to the minced fat and incubated at 37°C for 20 min with shaking.  The 
cell suspension was filtered through a 100-μm filter and then spun at 300 g for 10 
min to separate floating adipocytes from the SVF pellet. The SVF pellet was then 
resuspended in 3 ml of ACK lysis buffer and incubated at RT for 5 min to lyse red 
blood cell, followed by dilution in 10 ml of PBS.  The cells were then washed 
twice with PBS. 
 
Flow Cytometry 
For all studies, stromal vascular, bone marrow, peritoneal and white blood 
cells were first incubated with Fc block for 5 min at RT, followed by incubation for 
20 min at 4 ºC with fluorophore-conjugated antibodies. All conjugated antibodies 
were used at a 1:100 dilution unless otherwise indicated. 
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Chapter III: F4/80-APC (eBioscience), Ly6C-FITC (BD Biosciences), Ly6G-PE 
(1:200) (BD Biosciences), CD11b-APC-Cy7 (BD Bioscience).  
 
Chapter IV: F4/80-APC (eBioscience), Ly6C-FITC (BD Biosciences), CD11b-
APC-Cy7 (BD Biosciences), CD11c-PeCy7 (BD Biosciences) and Ly6G-PE 
(1:200) (BD Bioscience), Siglec-F PE (BD Biosciences), IgG2aκ PE isotype 
control (BD Biosciences), CCR3 PE (1:10) (R&D Biosystems).  
Chapter V: CD19 APC, CD11b APC-Cy7, Ly6G PE, Ly6C FITC, TCRβ APC, 
CD4 A700 (1:50), and CD8 Pe-Cy7 (BD Biosciences, Franklin Lakes, NJ).  
In all studies, 4,6-diamidino-2-phenyllindole (DAPI) (0.2 μg/ml) was added 
to each sample as a viability stain 10 min before flow cytometry analysis. Cells 
were processed using a 5 Laser LSRII machine in the Vanderbilt Flow Cytometry 
Core. All data were analyzed using FlowJo software version 7.6.1.  
 
AT Lysates 
Chapter IV & V: The epididymal fat pads were collected at the end of the study, 
flash frozen and kept at -80 ºC until utilized. Approximately 50 mg of AT were 
homogenized in 250 μl of lysis buffer (20 mM Tris HCl, 150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 0.5% NP-40, 2.5 mM sodium pyrophosphate, 1 mM sodium 
orthovanadate and 1 mM PMSF).  The protein concentration in the lysate was 
quantified using the Lowry method (94) with samples diluted in 0.1N NaOH, 0.1% 
SDS. 
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IFNγ and IL4 ELISA 
IFNγ and IL4 ELISAs were performed on AT lysates using BD Biosciences 
OptEIA ELISA kits according to the manufacturer’s instructions; 50 μg of total 
protein per well was used.  
 
Cell sorting 
Cells were collected and stained as described above for the flow 
cytometry section. The cells were sorted using a FACS Aria I sorter at the 
Vanderbilt Flow Cytometry Core. The CD11bloF4/80lo and CD11bhiF4/80hi 
populations were isolated for RNA expression and histological analysis. 
 
Western Blot Analysis 
Protein samples were collected by homogenizing c.a. 50 mg of liver, 
gastroctnemius muscle and/or AT in 750 μl, 500 μl and 250 μl of lysis buffer, 
respectively. Protein concentration was measured using the Lowry method. 
Western blot analysis was conducted as previously described (95). 
 
Glycosidase Assay  
Chapter V: A glycosidase assay was performed according to the manufacturer’s 
instructions (New England Biolabs Inc., Ipswich, MA). Briefly, aliquots of 20 μg of 
37 
 
protein extracts from livers of WT and C5D mice were incubated with 1 μl of 10X 
glycoprotein denaturing buffer. The protein was then denatured by heating 
reaction at 100 ºC for 10 min. Subsequently, 2 μl of 10X G7 reaction buffer, 2μl of 
N-glycosidase F enzyme and H2O up to a total volume of 20 μl were added. The 
reaction was incubated at 37 ºC for 1 h prior to performing Western blot analysis 
as previously described. 
Statistical Analysis 
GraphPad Prism 4.0 software was used for all statistical analyses. Data 
was analyzed using two-tailed unpaired t-tests to determine differences between 
two groups with 1 variable; one way ANOVA when more than two measurements 
were compared and two way ANOVA to compare measurements with two 
different variables (i.e. GTTs, Diet versus Genotype Effects). Outliers were 
excluded from the data for each individual parameter if outside the range of the 
mean ±2SD, and P≤0.05 was considered significant. 
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CHAPTER III 
 
HEMATOPOIETIC LEPTIN RECEPTOR DEFICIENCY DOES NOT AFFECT 
MACROPHAGE ACCUMULATION IN ADIPOSE TISSUE OR SYSTEMIC 
INSULIN RESISTANCE 
(Adapted from Gutierrez et al. J. Endocrinol. 2012; 212, 343-351) 
INTRODUCTION 
Accumulation of inflammatory macrophages in AT during obesity has been 
shown to correlate with AT inflammation and subsequent IR (19, 24). In addition, 
the polarization of the infiltrating macrophages is known to be an important factor 
in the inflammatory state of AT (47, 93, 96). Thus, understanding the 
mechanism(s) of macrophage recruitment to AT could lead to the development of 
therapies against IR and T2DM.  Adipokines, which are hormones secreted from 
AT, could act as chemoattractants and contribute to macrophage recruitment into 
AT.  The adipokine leptin has emerged as a strong candidate given its known 
role in immune regulation (97). Leptin is a 16 kDa soluble protein encoded by the 
Ob gene and is expressed primarily by white AT, such that circulating levels of 
leptin are positively correlated with levels of adiposity and AT macrophage 
accumulation (16, 33). 
 Leptin acts primarily through the long form of the leptin receptor (LepR) 
and plays an important role in weight regulation through its action in the 
hypothalamus (70). Mice that lack either leptin or the LepR are characterized by 
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severe hyperphagia and morbid obesity, as well as other hormonal abnormalities 
(72).  
Previous studies have shown that leptin promotes neutrophil and 
monocyte chemotaxis; as well as the activation of monocytes/macrophages 
leading to secretion of pro-inflammatory cytokines and the upregulation of 
inducible nitric oxide synthase (iNOS) (43, 98, 99). We have shown that leptin is 
a potent monocyte chemoattractant in vitro and that this chemotaxis is LepR-
dependent (43).  In addition, we have shown that expression of Emr1 (the gene 
for F4/80) in AT, which is an indicator of macrophage infiltration, is positively 
correlated with circulating levels of leptin during obesity (Figure 3.1) (r2 = 0.6973; 
P<0.0001) (33).  Given that leptin is primarily secreted from AT and that its 
circulating levels are positively correlated with increases in macrophage 
infiltration, we hypothesized that leptin could act as a monocyte chemoattractant 
that regulates macrophage recruitment to AT during obesity. 
  We designed a bone marrow transplant study to determine if 
hematopoietic deficiency of the functional long-form of the LepR would lead to 
decreases in macrophage recruitment to AT during HFD feeding. We 
transplanted bone marrow from LepR-/- and DKO (LepR-/-; CCR2-/-) mice into wild 
type (WT) recipients and placed these mice on a HFD for 6 or 12 weeks.  These 
time points were chosen because of previously shown kinetics of macrophage 
recruitment to AT (56). We examined macrophage infiltration to AT by flow 
cytometry, histology and real-time RT-PCR.  Our data provides evidence that 
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hematopoietic deficiency of the LepR does not affect macrophage recruitment to 
AT or insulin sensitivity during HFD-induced obesity. 
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Figure 3.1 Emr1 expression in AT is positively correlated to plasma leptin 
levels. 
Data from Coenen et al. (33) previously published by our group was re-analyzed 
and plotted as Emr1 expression (arbitrary units) versus plasma leptin levels (ng/ 
ml). (n = 41 mice). 
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RESULTS 
 
C57BL/6 mice were transplanted with either LepR+/+, LepR-/- or DKO 
(LepR-/-; CCR2-/-) bone marrow at 8 weeks of age. Four weeks after transplant 
mice were placed on a 60% diet (HFD) for 6 or 12 weeks (Figure 2.1). The BM-
LepR+/+ controls in this study were also used as negative controls for the study 
performed simultaneously and presented in Chapter IV of this dissertation. 
Recipients of CCR2-/- marrow (BM-CCR2-/-) were included in Chapter IV as well. 
There were no significant differences in any parameter studied between the BM-
CCR2-/- and BM-DKO (LepR-/-; CCR2-/-) mice.  Thus, only the BM-DKO mice are 
shown in this chapter. 
Metabolic Profile 
 There were no differences in body weight (Figure 3.2A) or food intake 
(data not shown) between the groups at any point during the study. Likewise, 
there were no differences in adiposity among genotypes at any time, although all 
groups increased in adiposity after 6 and 12 weeks of HFD feeding (Figure 3.2B). 
Epididymal fat pad weight (Figure 3.2C) and circulating leptin levels (Figure 3.2D) 
were not different among genotypes at any time point. In accordance with the 
NMR adiposity data, epididymal AT weight and leptin levels were generally 
elevated between the 6 and 12 week time points for each group (Figure 3.2C-D). 
Glucose and insulin tolerance tests were performed after 6 (Figure 3.3A & C) and 
12 (Figure 3.3B & D) weeks of HFD feeding. All groups responded similarly to the 
intraperitoneal glucose and insulin challenges after both periods of HFD feeding. 
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In general, fasting insulin levels were increased for all groups between the 
baseline measurements and 12 weeks of HFD feeding (Figure 3.3E). Fasting 
glucose levels were significantly increased (P<0.001) in all groups between the 
pre-HFD and both the 6 and 12 week time points (Figure 3.3F). 
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Figure 3.2 Metabolic Phenotyping. 
A) Average weekly body weight of BM-LepR+/+, BM-LepR-/- and BM-DKO mice 
pre- and post-HFD. B) Percent adiposity (total fat tissue divided by total body 
weight) determined by nuclear magnetic resonance.   C) Epididymal AT weight.  
D) Circulating plasma leptin levels assessed by ELISA.  Data are presented as 
mean ± SEM.  For pre-HFD up to 6 weeks post-HFD, n=20 mice per group.  For 
12 weeks post-HFD, n=9-10 mice per group. 
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Figure 3.3 All groups have similar glucose and insulin tolerance.Glucose 
tolerance tests were performed by injecting mice intraperitoneally with dextrose 
at a concentration of 2g (6 weeks) or 1g (12 weeks) per kilogram of lean mass 
after a 5 h morning fast. Glucose tolerance curves for all groups after A) 6 weeks 
and B) 12 weeks of HFD feeding. Insulin tolerance tests were performed by 
injecting mice intraperitoneally with 0.4 U (6 weeks) or 0.5 U (12 weeks) human 
insulin per kilogram of lean mass after a 5 h morning fast. Insulin tolerance 
curves for all groups after C) 6 weeks and D) 12 weeks of HFD feeding. E) 
Fasting insulin levels were measured by ELISA at the pre-HFD, 6 and 12 weeks 
time points. F) Fasting glucose levels were assessed at the pre-HFD, 6 and 12 
weeks time points.  Data are presented as mean ± SEM.  For GTT and ITT data, 
n=9-10 mice per group for 6 week data and n=5 mice per group for 12 week 
data.  For fasting insulin and glucose data, n= 8-10 per group. 
*** P<0.001 for all groups between Pre-HFD and 6 or 12 weeks 
  
46 
 
Blood Monocytes 
Two phenotypic and functional subsets of mature blood monocytes have 
been described: Ly6Clo and Ly6Chi (100). The Ly6Chi circulating monocyte subset 
is thought to be the source of recruited inflammatory macrophages to inflamed 
tissues. The circulating levels of blood monocytes and neutrophils were 
assessed by flow cytometry after 12 weeks of HFD feeding by first gating on all 
live CD11b+ cells. The BM-LepR-/- mice had a ~40% (P<0.05) reduction in 
circulating Ly6Chi monocytes, and BM-DKO mice a ~90% (P<0.001) reduction, 
when compared to the BM-LepR+/+ controls (Figure 3.4A-D). No differences were 
observed in the Ly6Clo monocyte subset or the percentage of circulating 
neutrophils between groups (Figure 3.4E-F).  
 
Macrophage Accumulation in AT 
 The accumulation of macrophages in AT after 6 and 12 weeks of HFD 
feeding was evaluated by histology, real-time RT-PCR and flow cytometry. TBO 
staining showed that there were no overt differences in overall immune infiltration 
between groups after either period of HFD feeding (Figure 3.5A-F). Real-time 
RT-PCR gene expression analysis in total AT for the macrophage markers Emr1 
and Cd68 showed no differences between groups after 6 (Figure 3.5G) or 12 
weeks (Figure 3.5H) of HFD feeding.   
 The stromal vascular fraction (SVF) was separated from the adipocytes of 
the epididymal AT by collagenase digestion. Macrophages from the SVF were 
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quantified by flow cytometry using an antibody against F4/80. The representative 
histograms illustrate the percentage of live F4/80hi cells in the SVF after 6 (Figure 
3.6A-C) and 12 weeks (Figure 3.6D-F) of HFD feeding. Quantification of the 
percentage of F4/80hi cells in the SVF showed a significant decrease (P<0.05) in 
the BM-DKO group when compared to the BM-LepR+/+ and BM-LepR-/- groups 
after 6 weeks of HFD feeding (Figure 6G). There were no differences in the 
percentage of F4/80hi cells in the AT of any group after 12 weeks of HFD feeding 
(Figure 6H). The BM-DKO mice had an increase in a discrete F4/80lo myeloid 
population (Figure 3.6C, arrow) which is due to the deficiency in hematopoietic 
CCR2, as I have reported in Chapter IV of this dissertation (37). 
 
AT inflammatory State 
 The inflammatory state of total AT was determined by assessing the gene 
expression of several pro- and anti-inflammatory markers by real-time RT-PCR.  
Analysis of the expression of the inflammatory markers Tnf and Nos2 showed no 
differences in these genes among groups after 6 weeks on the HFD (Figure 
3.7A). There was a significant decrease (P<0.001) in Nos2 expression in the BM-
DKO group when compared to the BM-LepR+/+ and BM-LepR-/- groups at the 12 
week time point (Figure 3.7B).  Additionally, assessment of the anti-inflammatory 
“M2” markers Arg1, Mgl1 and Mgl2 showed that there was a significant increase 
(P<0.05) in Arg 1 expression in the BM-DKO mice in comparison to the BM-
LepR+/+ mice after 6 weeks of HFD feeding (Figure 3.7A).  Arg1, Mgl1 and Mgl2 
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were all significantly increased (P<0.05) in the BM-DKO group in comparison to 
the BM-LepR+/+ and/or BM-LepR-/- groups after 12 weeks of HFD (Figure 3.7B).  
Bone marrow LepR deficiency alone did not impact anti-inflammatory gene 
expression in AT. 
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Figure 3.4 BM-LepR-/- mice have decreased circulating inflammatory 
monocytes. 
Blood cells were isolated from 12 week HFD fed recipient mice and analyzed by 
flow cytometry. Representative plots showing expression of Ly6C after gating on 
all CD11b+ live cells. A) BM-LepR+/+ B) BM-LepR-/- C) BM-DKO. Quantification of 
the percentage of D) CD11b+Ly6Chi, E) CD11b+Ly6Clo and CD11b+Ly6Ghi cells in 
all groups (mean ± SEM; n = 4-5 mice per group). 
* P<0.05 between BM-LepR+/+ and BM-LepR-/- mice 
*** P<0.001 between BM-LepR+/+ and BM-DKO mice 
^ P<0.05 between BM-LepR-/- and BM-DKO mice. 
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Figure 3.5 Histology and real-time RT-PCR analysis of F4/80+ cells in AT.  
Representative AT TBO images of A) BM-LepR+/+, B) BM-LepR-/- and C) BM-
DKO mice after 6 weeks of HFD feeding. Representative AT TBO images of D) 
BM-LepR+/+, E) BM-LepR-/- and F) BM-DKO mice after 12 weeks of HFD feeding. 
Real-time RT-PCR gene expression analysis of Emr1 (F4/80 and Cd68 in total 
AT after G) 6 and H) 12 weeks of HFD feeding (mean ± SEM; n = 10 mice per 
group).  
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Figure 3.6 Flow cytometry analysis of stromal vascular cells 
Stromal vascular cells were isolated and the percentage of live F4/80+ cells was 
quantified. Representative histograms of F4/80hi cells for A) BM-LepR+/+  B) BM-
LepR-/- and C) BM-DKO mice after 6 weeks of HFD feeding; D) BM-LepR+/+ , E) 
BM-LepR-/- and F) BM-DKO mice after 12 weeks of HFD feeding.  G-H) 
Quantification of the percentage of F4/80hi live cells in the SVF of all groups after 
6 or 12 weeks of HFD feeding.  Data presented as mean ± SEM. (n=4-5).  Arrow 
indicates F4/80lo cells found in BM-DKO mice. 
* P<0.05 between BM-LepR+/+ and BM-DKO mice 
^ P<0.05 between BM-LepR-/- and BM-DKO mice 
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Figure 3.7 Pro- and anti-inflammatory gene expression.  
Real-time RT-PCR gene expression analysis of pro- and anti-inflammatory 
markers was performed on RNA isolated from total AT. Expression of Tnf, Nos2, 
Arg1, Mgl1 and Mgl2 in all groups after A) 6 weeks and B) 12 weeks of HFD 
feeding (mean ± SEM; n = 10 mice per group).  
* P<0.05 between BM-LepR+/+ and BM-DKO mice 
** P<0.01 between BM-LepR+/+ and BM-DKO mice 
*** P<0.001 between BM-LepR+/+ and BM-DKO mice 
^ P<0.05 between BM-LepR-/- and BM-DKO mice 
  
53 
 
DISCUSSION 
 
Inflammatory macrophage infiltration into AT during obesity has been 
shown to be temporally correlated with local and systemic inflammation and IR 
(19, 24, 47, 50). Several genetic models that either disrupt macrophage 
recruitment to AT (30, 35, 38, 52) or promote an AT macrophage switch towards 
an “M2” or anti-inflammatory phenotype (52, 101, 102) have been explored. 
Despite the great progress made in this field in the past decade, methods to 
actively decrease macrophage recruitment to AT or diminish their inflammatory 
impact on this tissue are poorly understood.  
 We and others have shown that the adipokine leptin plays an important 
role in macrophage chemotaxis in vitro directly via its ability to act as a 
macrophage chemoattractant (43) or indirectly through the upregulation of 
adhesion molecules on endothelial cells (103).  Additionally, leptin has been 
shown to play a role in eosinophil (104) and neutrophil (105, 106) chemotaxis. 
These findings have led to the speculation that leptin, which is mainly produced 
in AT and has potent monocyte chemotactic activity, could be an important 
mediator of monocyte/macrophage chemotaxis to AT, where this adipokine is 
mainly produced (21, 42, 44, 45, 107-110). This is of particular interest during the 
initial stages of inflammatory macrophage accumulation in AT when recruitment 
is positively correlated with adiposity and circulating leptin levels (Figure 3.1) 
(33). However, this hypothesis had not been tested in vivo. In this study we 
assessed whether hematopoietic LepR deficiency led to a disruption in 
54 
 
macrophage recruitment to AT during obesity with the hypothesis that BM-LepR-/- 
chimeras would have reduced macrophage accumulation and improvements in 
glucose and insulin tolerance. Given that compensation by other cytokines was 
possible, we generated BM-DKO chimeras that have a hematopoietic deficiency 
in both LepR and CCR2.  
 Our results showed that hematopoietic LepR deficiency led to a significant 
decrease in the percentage circulating Ly6Chi monocytes (Figure 3.4B & D).  A 
similar but more dramatic phenotype has been observed in mice with CCR2 
deficiency (37, 111), in which Ly6Chi monocytes fail to egress from the bone 
marrow. In fact, the BM-DKO mice showed an identical phenotype to that of the 
BM-CCR2-/- mice in Chapter IV of this document (Figure 3.4C-D), indicating that 
having both CCR2 and LepR deficiency does not confer an additive or synergistic 
effect on the decreases in circulating inflammatory monocyte levels. The 
mechanism responsible for the reduction of Ly6Chi monocytes in BM-LepR-/- mice 
is unknown; however, because the levels of circulating monocytes in the BM-
DKO mice are identical to those of the BM-CCR2-/- mice, it is likely that the BM-
LepR-/- mutation is not affecting inflammatory monocyte egress but instead their 
proliferation and/or differentiation in the bone marrow. This hypothesis remains to 
be tested. 
The main end point of this study was to determine if the deficiency of 
LepR led to a reduction in macrophage recruitment to AT. Previous studies have 
shown that the initial process of inflammatory macrophage accumulation in AT 
occurs between 6 and 12 weeks of HFD feeding (56, 112); thus, we used these 
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time points to assess macrophage accumulation using multiple approaches. Our 
histology (Figure 3.5A-F), gene expression (Figure 3.5G-H) and flow cytometry 
(Figure 3.6) data showed no protective effect of LepR deficiency on macrophage 
accumulation in AT after 6 or 12 weeks of HFD feeding. There was a significant 
decrease (P<0.05) in the percentage of F4/80hi macrophages in the BM-DKO 
group after 6 weeks of HFD feeding (Figure 3.6G); however, this can be 
accounted for by the hematopoietic CCR2 deficiency, which leads to a decrease 
in F4/80hi cells and the accumulation of F4/80lo cells as I show in Chapter IV of 
this dissertation. In addition, no changes in glucose or insulin tolerance were 
observed between the three groups (Figure 3A-D) despite the fact that all mice 
became hyperglycemic and hyperinsulinemic in response to the HFD feeding 
(Figure 3E-F). Thus, we can conclude that hematopoietic LepR deficiency alone 
or in combination with hematopoietic CCR2 deficiency does not affect 
inflammatory macrophage recruitment to AT or insulin sensitivity after 6 or 12 
weeks of HFD feeding. 
The negative results are not a consequence of the inability of these mice 
to have increased macrophage infiltration, become insulin resistant or glucose 
intolerant during HFD feeding. We performed an additional study in which we 
show that LepR+/+ mice fed a HFD have increased macrophage infiltration 
(P<0.01), glucose intolerance (P<0.001) and IR (P<0.01) when compared to 
LepR+/+ mice fed a chow diet (Figure 3.8). Thus, within the limits of the sensitivity 
of our assays, hematopoietic LepR deficiency does not affect macrophage 
recruitment or insulin sensitivity during obesity.  
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Similar negative results have been obtained by our group and others when 
assessing inflammatory macrophage recruitment to AT after deletion of a single 
chemokine or chemokine receptor (38-41, 113). Accordingly, the current study 
provides evidence for the redundancy of chemokines and chemokine receptors in 
the innate immune system. Despite the elimination of two receptors that mediate 
the function of four different chemokines (leptin, CCL2, CCL7 and CCL8) that are 
upregulated in the AT during obesity, macrophage infiltration to AT is not 
disrupted. This redundancy in the chemokine system reflects the importance of  
leukocyte chemotaxis in normal immune system function and  makes it “robust” 
to naturally occurring mutations (114). 
Previously published studies suggest that in vitro leptin treatment leads to 
the activation of monocyte/macrophages and have shown a dose-dependent 
induction of inflammatory mediators such as IL-6 and TNF-α (98). Macrophages 
are primarily responsible for AT inflammation during obesity (18, 19, 22); thus, 
we tested whether hematopoietic LepR deficiency led to changes in the 
inflammatory state of total AT by real-time RT-PCR. Our results showed no 
differences in pro- or anti-inflammatory marker gene expression between BM-
LepR+/+ and BM-LepR-/- mice after any period of HFD feeding (Figure 3.7A-B). 
Significant differences were observed in the inflammatory gene expression of 
BM-DKO mice; however, these are similar to the changes in gene expression 
found in the BM-CCR2-/- mice (Chapter IV). As with macrophage chemotaxis, the 
effects of leptin on inflammatory gene expression that have been found in vitro 
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are likely compensated  in vivo by other cytokines found in the AT environment 
during obesity. 
In conclusion, our study provides evidence that despite the potency of 
leptin as a monocyte/macrophage chemoattractant (43), hematopoietic 
deficiency of its functional receptor does not affect macrophage accumulation in 
AT.  Our current finding that hematopoietic LepR deficiency decreases the 
number of circulating Ly6Chi monocyte levels should be further studied as it could 
provide a novel role for leptin in hematopoiesis and/or myeloid cell migration.  
Our results do not rule out the possibility that leptin can affect macrophage 
infiltration into AT through the upregulation of adhesion molecules in the 
endothelial cells of the SVF, as has been previously suggested by Curat et al. 
(103). 
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Figure 3.8  LepR+/+ mice fed a HFD have increased macrophage infiltration 
and become glucose intolerant and insulin resistant. 
LepR+/+ mice were placed on either a chow or high fat diet for 6 weeks. A) 
Glucose tolerance test, using 1 g of dextrose per kg of lean mass after a 5 hour 
fast. B) Fasting insulin levels. C) Flow cytometric percentage of CD11bhiF4/80hi 
cells from all live stromal vascular cells. D) Emr1 expression in total epididymal 
AT. Data presented as mean ± SEM (n = 5 per group). 
*P<0.05 between diets 
**P<0.01 between diets 
***P<0.001 between diets 
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CHAPTER IV 
 
ABERRANT ACCUMULATION OF EOSINOPHILS IN THE ADIPOSE TISSUE 
OF CCR2 DEFICIENT MICE PROMOTES ALTERNATIVE MACROPHAGE 
ACTIVATION AND DELAYS IMPROVEMENTS IN INSULIN SENSITIVITY 
 
(Adapted from: Gutierrez et al. Diabetes 60: 2820-2829, 2011 and Gutierrez et al. 
Manuscript in Preparation, 2012) 
 
INTRODUCTION 
 Obesity is an independent risk factor for type 2 diabetes, cardiovascular 
disease, fatty liver disease, atherosclerosis, and several cancers. Chronic AT 
inflammation is a cardinal feature of obesity that leads to other health 
complications such as IR (9, 115, 116).  Recruitment of macrophages is an 
important factor in AT inflammation (24) and has been shown to be temporally 
associated with IR (50, 117).   
CCR2 regulates monocyte chemotaxis through direct interactions with its 
ligands, monocyte chemoattractant proteins-1 and -3 (MCP-1, and -3) (118). 
CCR2-/- mice have an immune deficiency in Th1 responses characterized by low 
levels of IFNγ production and delayed macrophage recruitment to sites of 
inflammation (74). Studies by Tsou et al. found that the CCR2-/- mice have a 
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defect in the egress of inflammatory monocytes from the bone marrow, resulting 
in a dramatic reduction of these cells in the circulation (111, 119).  
The role of CCR2 and MCP-1 in macrophage recruitment to AT and the 
liver, and their contribution to IR has been evaluated by various groups (30, 35, 
39, 120-122). One study showed that obese CCR2-/- mice have a modest 
decrease in macrophage marker expression in AT and ATM number after 24 
weeks on a 60% fat diet when compared to wild-type controls (35).  Additionally, 
a bone marrow transplant (BMT) study showed that hematopoietic CCR2 
deficiency leads to decreased F4/80 expression in the AT of obese ob/ob mice 
(120).  These experiments indicate that substantial obesity (i.e. long periods of 
HFD feeding and/or a genetically morbidly obese model) is required before 
differences in macrophage recruitment and improvements in insulin sensitivity 
are observed in CCR2-/- mice, despite their striking reduction in circulating 
inflammatory monocytes. We set out to investigate the mechanism responsible 
for the delayed protection in AT inflammation and macrophage recruitment in 
global and hematopoietic models of CCR2 deficiency (CCR2-/- and BM-CCR2-/-, 
respectively). 
  In this study we analyzed the changes in myeloid populations that take 
place in the AT of CCR2-/- and BM-CCR2-/- mice and contrasted them to changes 
in CCR2+/+ and BM-CCR2+/+ controls.  Our data showed that global and 
hematopoietic CCR2 deficiency leads to the accumulation of Siglec-
F+CD11bloF4/80lo eosinophils during early periods of HFD feeding. The AT 
eosinophilia is associated with increased expression of anti-inflammatory 
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markers in total AT. Surprisingly no improvements in systemic metabolism are 
observed until after the eosinophils are no longer found in AT after extended 
periods of HFD feeding. 
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RESULTS 
 
Part I: (Gutierrez et al. Diabetes 60: 2820-2829, 2011) 
 
Weight and Adiposity. 
  Four weeks post-BMT, BM-CCR2-/- and BM-CCR2+/+ mice were placed 
on a HFD for 6, 12 or 20 weeks. The recipient groups had similar weight gain, 
adiposity, and epididymal fat pad weight throughout the study (Figure 4.1). In 
addition, there were no differences in food intake between groups (data not 
shown).  
 
Immunophenotype of Circulating Monocytes. 
 BM-CCR2-/- mice fed a HFD for 12 weeks had a 10-fold reduction in the 
percentage of circulating Ly6Chi monocytes (P<0.001; Figure 4.2A - C) when 
compared to the BM-CCR2+/+ mice.  The percentage of Ly6Clo cells was not 
affected in the BM-CCR2-/- mice (Figure 4.2D). CCR2-/- mice fed a HFD for 12 
weeks presented a similar reduction in Ly6Chi monocytes when compared to 
CCR2+/+ controls (Figure 4.3A & D). We also analyzed the expression of CD11c 
and F4/80 in blood monocytes of CCR2+/+ and CCR2-/- mice fed either a HFD or 
chow diet (CD) for 12 weeks (Figures 4.3 & 4.4). Interestingly, the ly6Clo 
population from HFD-fed CCR2-/- mice had increased CD11c expression 
(rightward shift of blue line in Figure 4.3E) compared to the Ly6Clo cells from 
HFD-fed CCR2+/+ mice (Figure 4.4B). In the general interest of assessing the 
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effects of HFD feeding on the imunophenotype of circulating monocytes we 
investigated monocytes isolated from HFD and CD-fed CCR2+/+ mice. As 
previously shown (123, 124), a comparison of HFD-fed and CD-fed CCR2+/+ mice 
showed a small increase in expression of CD11c in Ly6Chi monocytes while the 
expression of CD11c in Ly6Clo monocytes remained unaffected during HFD 
feeding (Figure 4.4B & F).  
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 Figure 4.1 BM-CCR2-/- and BM-CCR2+/+ mice have similar metabolic  
Parameters.  
A) Weight gain curves of BM-CCR2+/+ and BM-CCR2-/- mice during 20 weeks of 
HFD feeding (mean ± SEM; n = 9 mice per group). B) Percent adiposity in BM-
CCR2+/+ and BM-CCR2-/- mice after 6, 12 and 20 weeks on a HFD (mean ± SEM; 
n = 7-10 mice per group). Percent adiposity was calculated by dividing total AT 
mass, as assessed by NMR, by body weight.  C) Epididymal AT pad weight after 
6, 12 and 20 weeks on a HFD (mean ± SEM; n = 7-10 mice per group). 
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 Figure 4.2  BM-CCR2-/- mice have decreased levels of circulating 
 inflammatory monocytes.  
 White blood cells were isolated from BM-CCR2+/+ and BM-CCR2-/- mice fed a 
HFD for 12 weeks. Circulating monocyte levels were assessed by flow cytometry 
by first gating on all live CD11b+ cells. Representative pseudo-color flow 
cytometry plot of Ly6C expression in the A) BM-CCR2+/+ controls and B) BM-
CCR2-/- mice. Quantification of the percentage of circulating C) Ly6Chi monocytes 
and D) Ly6Clo monocytes in BM-CCR2+/+ and BM-CCR2-/- mice (mean ± SEM; n = 
4 mice per group). 
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Figure 4.3 CCR2-/- mice have decreased levels of blood Ly6Chi monocytes 
and increased expression of CD11c in Ly6Clo monocytes.  
White blood cells were isolated from CCR2+/+ and CCR2-/- mice fed a HFD for 12 
weeks. Circulating monocyte levels were assessed by flow cytometry by first 
gating on all live CD11b+ cells. A) Gates on Ly6Chi and ly6Clo populations in 
CCR2+/+ mice. B) Histogram of CD11c expression in Ly6Chi (red line) and Ly6Clo 
(blue line) monocytes in CCR2+/+ mice. C) Histogram of F4/80 expression in 
Ly6Chi (red line) and Ly6Clo (blue line) monocytes in CCR2+/+ mice D) Gates on 
Ly6Chi and ly6Clo populations in CCR2-/- mice. E) Histogram of CD11c 
expression in Ly6Chi (red line) and Ly6Clo (blue line) monocytes in CCR2-/- mice. 
F) Histogram of F4/80 expression in Ly6Chi (red line) and Ly6Clo (blue line) 
monocytes in CCR2-/- mice. “N” in panels A & D indicate neutrophil populations. 
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Supplementary Figure 4.4 HFD feeding increases the numbers and the 
CD11c expression of Ly6Chi monocytes in CCR2+/+ mice.  
White blood cells were isolated from CCR2+/+ mice fed a HFD or CD for 12 
weeks. Circulating monocyte levels were assessed by flow cytometry by first 
gating on all live CD11b+ cells. A) Gates on Ly6Chi and ly6Clo populations in HFD 
fed CCR2+/+ mice. B) Histogram of CD11c expression in Ly6Chi (red line) and 
Ly6Clo (blue line) monocytes in HFD fed CCR2+/+ mice. C) Histogram of F4/80 
expression in Ly6Chi (red line) and Ly6Clo (blue line) monocytes in HFD fed 
CCR2+/+ mice. D) Gates on Ly6Chi and ly6Clo populations in CD fed CCR2+/+ 
mice. E) Histogram of CD11c expression in Ly6Chi (red line) and Ly6Clo (blue 
line) monocytes in CD fed CCR2+/+ mice. F) Histogram of F4/80 expression in 
Ly6Chi (red line) and Ly6Clo (blue line) monocytes in CD fed CCR2+/+ mice. “N” in 
panels A & D indicate neutrophil populations. 
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Glucose Tolerance and Insulin Sensitivity. 
 
 To examine the systemic metabolic effects of CCR2 deficiency we 
performed glucose and insulin tolerance tests. We found no differences in 
glucose or insulin tolerance between groups at the 6 or 12 week time points 
(Figure 4.5A-D). However, a modest improvement in glucose tolerance was 
found in the BM-CCR2-/- mice (P<0.05), 15 min post glucose injection, after 20 
weeks of HFD feeding (Figure 4.5E). Fasting glucose and insulin levels were not 
different between groups at any time (Table 4.1). Similar results were obtained in 
the global CCR2-/- mice in which differences in glucose tolerance were not 
observed until after 20 weeks of HFD feeding (Figure 4.6A-C). The discrepancy 
in glucose tolerance between the hematopoietic and global CCR2 deficient 
models can be attributed the inability of the BMT model to gain weight (125). On 
average, BM-CCR2-/- mice weighed <40g after 20 weeks of HFD feeding while 
the CCR2-/- weighed >48g during the same HFD feeding period. 
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Figure 4.5. BM-CCR2-/- mice have a modest improvement in glucose 
tolerance after extended periods of HFD feeding. All GTT and ITT 
experiments were performed by injecting mice with either dextrose (1 g/Kg of 
lean mass) or insulin 0.5 (U/Kg of leans mass) after a 5 h morning fast.  A) GTT 
after 6 weeks of HFD feeding (mean ± SEM; n = 8-10 mice per group). B) ITT 
after 6 weeks of HFD feeding (mean ± SEM; n = 4-5 mice per group). C) GTT 
after 12 weeks of HFD feeding (mean ± SEM; n = 3-5 mice per group). D) ITT 
after 12 weeks of HFD feeding (mean ± SEM; n = 7-10 mice per group) E) GTT 
after 20 weeks of HFD feeding (mean ± SEM; n = 8-9 mice per group). F) ITT 
after 20 weeks on a HFD (mean ± SEM; n = 9 mice per group).  
*P<0.05 compared to the BM-CCR2+/+ group at the 15 min time point. 
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Figure 4.6 HFD fed CCR2-/- mice have delayed improvements in glucose 
tolerance.  
Glucose tolerance curves of mice injected with 1 g of dextrose per kg of lean 
body mass. A) GTT curve of CCR2+/+ and CCR2-/- mice after 6 weeks on either a 
HFD or CD (mean ± SEM; n = 3-9 mice per group). Both CD groups are 
significantly more glucose tolerant than both HFD groups (P<0.05). B) GTT curve 
of CCR2+/+ and CCR2-/- mice after 12 weeks on either a HFD or CD (mean ± 
SEM; n = 2-8 mice per group). Both CD groups are significantly more glucose 
tolerant than both HFD groups (P<0.05). C) GTT curve of CCR2+/+ and CCR2-/- 
mice after 20 weeks on a HFD (mean ± SEM; n = 4 mice per group). *P<0.05, 
**P<0.01 compared to CCR2+/+ at the 20 week time point. 
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Table 4.1 No differences in fasting insulin or glucose levels were detected 
between the BM-CCR2+/+ and BM-CCR2-/- mice. 
 
Fasting glucose levels were assessed after a 5 h morning fast. Fasting insulin 
and were measured by ELISA. (mean ± SEM; n = 7-10 mice per group).  
 
   BM-CCR2
+/+ BM-CCR2-/- 
Insulin (ng/ml)   
  6 wks 0.54 ± 0.24 0.60 ± 0.19 
  12 wks 0.98 ± 0.76 1.18 ± 1.27 
  20 wks 1.50 ± 0.33 2.27 ± 0.67 
Glucose (mg/dl)   
  6 wks 156 ± 29 178 ± 26 
  12 wks 164 ± 20 180 ± 34 
  20 wks 282 ± 51 257 ± 30 
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AT Inflammatory State: Several reports indicate that CCR2-/- mice have 
deficient Th1 responses characterized by a low number of antigen presenting 
cells (APCs), resulting in reduced levels of the Th1 cytokine IFNγ (126, 127) 
and/or elevated IL4 (128). Assessment of IFNγ and IL4 in AT lysates from BM-
CCR2-/- and BM-CCR2+/+ mice showed no differences in these cytokines levels 
between groups after any period of HFD feeding (Figure 4.7A-B).  Gene 
expression of the inflammatory genes TNFα (Tnf) and iNOS (Nos2) was not 
different between groups at the 6 and 12 week time points (Figure 4.7C & D); 
however, TNFα expression was significantly lower in the BM-CCR2-/- mice after 
20 weeks of HFD feeding (P<0.05) (Figure 4.7E). Gene expression of the 
chemokines MCP-1 (Ccl2) and MIP-1α (Ccl3) were significantly increased after 6 
weeks (P<0.01 and P<0.001, respectively) and 12 weeks (P<0.05 and P<0.01, 
respectively) in the BM-CCR2-/- mice; no differences in the expression of these 
chemokines were observed in the mice fed a HFD for 20 weeks.    
The BM-CCR2-/- mice presented a 3-fold increase in the expression of the 
anti-inflammatory marker arginase 1 (Arg1) at 6 (P<0.01) and 12 weeks 
(P<0.01); expression of this gene was not different between groups after 20 
weeks of HFD feeding (Figure 4.7C-E).  Expression of Cd163, mgl1, mgl2 and 
Il10 was assessed and these “M2” or anti-inflammatory genes were generally 
increased in the BM-CCR2-/- mice after 6 and 12 weeks of HFD feeding but not at 
the 20 week time point, when compared to the BM-CCR2+/+ control.   
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Figure 4.7 BM-CCR2-/- mice have similar levels of IFNγ and IL4 protein in AT 
to those of BM-CCR2+/+ controls after all periods of HFD.  
A) Levels of IFNγ protein in AT lysates were measured by ELISA (mean ± SEM; 
n = 7-10 mice per group). B)  Levels of IL4 protein in AT lysates were measured 
by ELISA (mean ± SEM; n = 6-7 mice per group). C-E) RNA was isolated from 
AT and used for gene expression analysis by real-time RT-PCR. The mRNA 
expression of Tnf, Nos2, Ccl2, Ccl3, Arg1, Cd163, Mgl1, Mgl2 and Il10 was 
assessed after 6, 12 and 20 weeks of HFD feeding and plotted as expression 
relative to the BM-CCR2+/+ group of each time point (mean ± SEM; n = 7-10 mice 
per group). 
*P<0.05 compared to the BM-CCR2+/+ group  
**P<0.01 compared to the BM-CCR2+/+ group  
***P<0.001 compared to the BM-CCR2+/+ group  
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Immune Cell Infiltration into AT:  Crown-like structures (CLS), which are an 
accumulation of immune cells around presumably dead adipocytes, were used to 
quantify immune cell infiltration in TBO stained sections of AT (Figure 4.8A-F). 
There were no differences in numbers of CLS between BM-CCR2-/- and BM-
CCR2+/+ mice after 6 or 12 weeks of HFD feeding (Figure 4.8G).  However, there 
was a significant decrease in CLS in the BM-CCR2-/- mice after 20 weeks of HFD 
feeding (P<0.05) (Figure 4.8E-G). Further analysis of TBO stained AT from mice 
fed a HFD for 20 weeks showed that the number of CLS is dependent on the 
body weight of the mouse. There were no differences between weight matched 
BM-CCR2-/- and BM-CCR2+/+ mice under 40g of body weight; conversely, there 
was a decrease in CLS in the BM-CCR2-/- mice when compared to weight-
matched BM-CCR2+/+ controls over 45g of body weight (Figure 4.9). In 
accordance with our histological data, there were no differences in the 
expression of CD68 (Cd68), CD11b (Itgam) or CD11c (Itgax) in AT of BM-CCR2-
/- compared to BM-CCR2+/+ mice after 6 or 12 weeks of HFD feeding (Figure 
4.8H-I); however, the expression of these genes was significantly lower for the 
BM-CCR2-/- mice by the 20 week time point when compared to the control group 
(P<0.05; Figure 4.8J). The expression of F4/80 (Emr1) in the AT of BM-CCR2-/- 
mice was significantly increased after 6 weeks (P<0.05), unchanged after 12 
weeks, and there was a trend towards a decrease after 20 weeks of HFD in 
comparison to the BM-CCR2+/+ controls (P<0.07; Figure 4.8H-J). 
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Figure 4.8 BM-CCR2-/- mice have decreased immune infiltration and 
macrophage marker expression after extended periods of HFD feeding.  
AT was collected from BM-CCR2+/+ and BM-CCR2-/- mice fed HFD for 6, 12, or 
20 weeks and used to assess macrophage infiltration by histological and gene 
expression analysis.  A - F) Representative TBO-stained images from mice as 
indicated. G) Crown-like structures (CLS) in TBO stained AT sections were 
quantified from 8 different fields per mouse and presented as number of CLS per 
field (mean ± SEM; n = 5-7 mice per group).  H-J) RNA was isolated from AT and 
used for gene expression analysis by real-time RT-PCR. The expression of the 
macrophage markers Emr1, Cd68, Itgam, and Itgax was assessed after 6, 12 
and 20 weeks of HFD feeding and plotted as expression relative to the BM-
CCR2+/+ group of each time point (mean ± SEM; n = 7-10 mice per group).  
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 Figure 4.9 BM-CCR2-/- mice have lower immune infiltration than weight- 
matched BM-CCR2+/+ mice.  
AT was collected from weight-matched BM-CCR2+/+ and BM-CCR2-/- mice fed 
HFD for 20 weeks and used to assess macrophage infiltration by histological 
analysis.  Representative TBO-stained AT pictures of weight-matched BM-
CCR2+/+ and BM-CCR2-/- mice are presented. 
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CCR2 deficiency leads to the aberrant accumulation of F4/80locells in AT: 
Based upon our observation that there were no changes in immune infiltration in 
AT after 6 and 12 weeks of HFD feeding despite the dramatic reduction in 
circulating inflammatory cells, we sought to further characterize the macrophages 
in AT by flow cytometry. To this end, we performed careful evaluation of the 
F4/80+ cells within AT.  Based on our gating strategy the BM-CCR2+/+ mice 
contained the expected F4/80- and F4/80hi populations (Figure 4.10A). 
Interestingly, the BM-CCR2-/- mice accumulated two discrete myeloid populations 
in their AT, F4/80lo and F4/80hi (Figures 4.10B).  The discrete F4/80lo population 
was observed in the SVF of the BM-CCR2-/- at the 6 (Figures 4.10B-C) and 12 
week (Figure 4.11B & Figure 4.10C) time points, but was no longer detected after 
20 weeks of HFD feeding (Figure 4.11D & Figures 4.10C).  
Real-time RT-PCR analysis of RNA isolated from whole AT of BM-CCR2-/- 
mice showed that the presence of the F4/80lo population at 6 and 12 weeks was 
associated with increases in gene expression of myeloperoxidase (Mpo; P<0.05), 
CXCR2 (IL8rb; P<0.01) Cxcl1 (P<0.001) and Cxcl2 (P<0.05) (Figure 4.10D & E). 
No differences in the expression of these genes were observed after 20 weeks of 
HFD, when the F4/80lo cells were no longer detected (Figure 4.10F).  
Similar to the BM-CCR2-/- model, analysis of the SVCs of the global 
CCR2-/- mice showed that CD11bloF4/80lo cells aberrantly accumulate in the AT 
of global CCR2-/- mice with similar kinetics. The cells accumulate in the AT of 
CCR2-/- after 6 or 12 weeks of HFD feeding (Figure 4.12D-E), while no discrete 
population was found in the CCR2+/+ controls (Figure 4.12A-B). Additionally, after 
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20 weeks of HFD feeding the CD11bloF4/80lo were no longer found in either the 
AT of CCR2-/- or CCR2+/+ mice (Figure 4.12F). Global CCR2-/- mice were utilized 
for subsequent characterization of the CD11bloF4/80lo cells. 
 
CD11bloF4/80lo Cell Characterization: CD11bhiF4/80hi and CD11bloF4/80lo cells 
were isolated from the AT of CCR2-/- mice 10 weeks post-HFD feeding by flow 
cytometry activated cell sorting (Figure 4.13A). Gene expression analysis was 
performed for both populations, and is presented as expression relative to the 
CD11bhiF4/80hi cells (Figure 4.13B). Expression of Emr1 was significantly lower 
for CD11bloF4/80lo cells as expected based on our gating strategy (P<0.001). 
The expression of Arg1 (P<0.05), Cd163 (P<0.001), Il10 (P<0.01), Il6 (P<0.01), 
Ccr5 (P<0.05), Ccl2 (P<0.01) and Csfr1 (P<0.001) was significantly lower in the 
CD11bloF4/80lo cells in comparison to the CD11bhiF4/80hi macrophages. 
Expression of Itgax (P<0.01), Nos2 (P<0.05), Ccl5 (P<0.01), Mpo (P<0.01), Il8rb 
(P<0.05) and Csf1 (P<0.05) was significantly higher for the CD11bloF4/80lo cells. 
H&E staining of the sorted CD11bloF4/80lo cells showed that these cells have a 
granulocytic/monocytic morphology and are smaller in size than the 
CD11bhiF4/80hi macrophages (Figure 4.13C). Despite several reports of 
neutrophilia at sites of inflammation in CCR2-/- mice (129, 130), flow cytometry 
analysis of the CD11bloF4/80lo population in the global CCR2-/- mice showed that 
these cells are Ly6G-negative and therefore unlikely to be neutrophils (Figure 
4.14).  
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Figure 4.10 A unique F4/80lo myeloid population accumulates in the SVF of 
the AT of BM-CCR2-/- mice.  
SVCs isolated from BM-CCR2+/+ and BM-CCR2-/- mice were analyzed by flow 
cytometry. Representative flow cytometry histogram of F4/80-expressing 
populations in a A) BM-CCR2+/+ mouse and in a B) BM-CCR2-/- mouse gated on 
all live cells. C) Quantification of F4/80lo vs. F4/80hi cell percentages after 6, 12 
and 20 weeks of HFD in the BM-CCR2-/- (mean ± SEM; n = 3-5).  D- F) RNA was 
isolated from AT and used for gene expression analysis by real-time RT-PCR. 
The mRNA expression of Mpo, Il8rb, Cxcl2 and Cxcl1 was assessed after 6, 12 
and 20 weeks of HFD feeding and plotted as expression relative to the BM-
CCR2+/+ group of each time point (mean ± SEM; n = 7-10 mice per group). 
*P<0.05 compared to the BM-CCR2+/+ group  
**P<0.01 compared to the BM-CCR2+/+ group  
***P<0.001 compared to the BM-CCR2+/+ group  
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Figure 4.11 BM-CCR2-/- mice have a unique CD11bF4/80lo population after 
12 weeks of HFD feeding.  
Representative histograms of F4/80+ cells for A) BM-CCR2+/+ and B) BM-CCR2-/- 
mice after 12 weeks of HFD feeding. Representative plots of CD11b+F4/80+ cells 
for C) BM-CCR2+/+ and D) BM-CCR2-/- mice after 20 weeks of HFD feeding.  
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Figure 4.12 CD11bloF4/80lo cells accumulate in global CCR2-/- mice.  
Representative contour plots of F4/80 versus CD11b expression in SVCs from  
CCR2+/+ mice after A) 6 Weeks B) 12 weeks and C) 20 weeks on a HFD. 
Representative contour plots of F4/80 versus CD11b expression in SVCs from 
CCR2-/- mice after A) 6 Weeks B) 12 weeks and C) 20 weeks on a HFD.  (n = 4 
biological replicates) 
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Figure 4.13 CD11bloF4/80lo cells have an inflammatory expression profile 
and a granulocytic morphology. 
 CD11bloF4/80lo and CD11bhiF4/80hi cells were isolated by fluorescence activated 
cell sorting from CCR2-/- mice fed a HFD for 10 weeks. A) Gating strategy used 
for cell sorting; CD11bhiF4/80hi (P1) and CD11bloF4/80lo (P2). RNA was isolated 
from the sorted cells and used for gene expression analysis by real-time RT-
PCR. B) Gene expression profiles in CD11bloF4/80lo (P2) cells relative to 
CD11bhiF4/80hi (P1) cells in CCR2-/- mice was assessed (mean ± SEM; n = 4 
biological replicates) C) Representative images of H&E stained CD11bhiF4/80hi 
(P1) and CD11bloF4/80lo (P2) cells. 
*P<0.05 compared to the CD11bhiF4/80hi 
**P<0.01 compared to the CD11bhiF4/80hi  
***P<0.001 compared to the CD11bhiF4/80hi 
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Figure 4.14 CD11bloF4/80lo cells have a Ly6G (negative) immunophenotype 
SVCs were isolated from the AT of CCR2-/- mice fed a HFD for 10 weeks. 
Representative image of gating strategy used to assess the expression of Ly6G 
in the CD11bloF4/80lo cells.  
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CD11bloF4/80lo Cells are Transiently Found in CCR2+/+ mice 
To determine the physiological relevance of the CD11bloF4/80lo cells in wild type 
conditions, we isolated CD11bloF4/80lo  and CD11bhiF4/80hi macrophages from 
CCR2+/+ mice fed a HFD for 7 weeks by fluorescence activated cell sorting using 
the gating strategy shown in Figure 4.13A.  Despite the absence of two discrete 
populations  in the CCR2+/+ mice we were able to isolate cells using the same 
gating strategy as in Figure 4.13A and found cells that have identical gene 
expression (Figure 4.15B) and morphology (Figure 4.15C) as the CD11bloF4/80lo 
cells isolated from the AT of CCR2-/- mice. In addition, we assessed if HFD 
feeding was necessary for the accumulation of CD11bloF4/80lo cells. The 
expression of several key genes in the CD11bloF4/80lo cells isolated from CD-fed 
CCR2-/- and CCR2+/+ mice (Figure 4.16) was similar to that of CD11bloF4/80lo 
cells isolated from the HFD mice (Figures 4.13B & 4.15B). 
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Figure 4.15 CD11bloF4/80lo cells are transiently found in the AT of HFD-fed 
CCR2+/+ mice 
CD11bloF4/80lo and CD11bhiF4/80hi cells were isolated by fluorescence activated 
cell sorting from CCR2+/+ mice fed a HFD for 7 weeks. A) Gating strategy used 
for cell sorting; CD11bhiF4/80hi (P1) and CD11bloF4/80lo (P2). RNA was isolated 
from the sorted cells and used for expression analysis of key CD11b loF4/80lo 
genes by real-time RT-PCR. B) Gene expression profiles in CD11bloF4/80lo (P2) 
cells relative to CD11bhiF4/80hi (P1) cells in CCR2+/+ mice was assessed (mean ± 
SEM; n = 4 biological replicates) C) Representative images of H&E stained 
CD11bhiF4/80hi (P1) and CD11bloF4/80lo (P2) cells. 
*P<0.05 compared to the CD11bhiF4/80hi 
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Figure 4.16 CD11bloF4/80lo cells are found in the AT of CD fed CCR2+/+ and 
CCR2-/- mice. 
SVCs were isolated from 14 weeks old CD fed CCR2+/+ and CCR2-/- mice. Gating 
strategy used for FACS sorting of CD11bloF4/80lo and CD11bhiF4/80hi cells in A) 
CCR2+/+ mice and B) CCR2-/- mice. B) Gene expression of key CD11bloF4/80lo 
genes relative to CD11bhiF4/80hi cells in C) CCR2+/+ mice and D) CCR2-/- mice (n 
= 3 pooled biological samples). 
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Part II: (Gutierrez et al. Manuscript in Preparation, 2012) 
CD11bloF4/80lo Myeloid Cells in the AT and Peritoneum are Eosinophils 
We reported in Part I of this chapter the discovery of a novel myeloid cell 
population in the peritoneal cavity and AT of CCR2-/- mice. Further analysis of 
their expression of extracellular markers indicated that the CD11bloF4/80lo cells in 
the peritoneum are Siglec-F+ and therefore eosinophils (Figure 4.17).  
 AT CD11bloF4/80lo cells were Siglec-F positive, suggesting that the 
CD11bloF4/80lo cells in AT are also a population of eosinophils. Isolation of these 
cells by flow activated cell sorting showed a combination of cells with eosinophil 
and monocyte morphology; however isolating the CD11bloF4/80lo Siglec-F+ 
population gives a homogenous cell population with eosinophil-like morphology 
(Figure 4.18).  
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Figure 4.17 Expression of Siglec-F in peritoneal CD11bloF4/80lo cells. 
Expression of Siglec-F in peritoneal CD11bloF4/80lo cells was assessed by flow 
cytometry analysis. Representative images of flow cytometry plots of peritoneal 
cells indicating the gates used on the CD11bloF4/80lo (blue) and CD11bhiF4/80hi 
(red) populations in A) CCR2+/+ and B) CCR2-/- mice. Representative histograms 
of Siglec-F expression in the CD11bloF4/80lo (blue) and CD11bhiF4/80hi (red) 
populations in C) CCR2+/+ and D) CCR2-/- mice.  
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Figure 4.18 AT CD11bloF4/80lo cells express siglec-F. Representative images 
of flow cytometry plots of SVF cells indicating the gates used on the 
CD11bloF4/80lo and CD11bhiF4/80hi populations in A) CCR2+/+ and B) CCR2-/- 
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mice. Representative histograms of Siglec-F expression in the CD11bloF4/80lo 
and CD11bhiF4/80hi populations in C) CCR2+/+ and D) CCR2-/- mice. E) Flow 
activated sorted CD11bloF4/80lo eosinophil stained with Diff-Quick. 
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Eosinophils are Found in All AT Depots 
 Once we established that the CD11bloF4/80lo cell population are 
eosinophils, we used expression of CD11b versus Siglec-F to accurately quantify 
the percentage of these cells in the AT of CCR2+/+ and CCR2-/- mice (Figure 
4.19). The percentage of eosinophils in the epididymal, peri-renal, mesenteric 
and subcutaneous AT depots of CCR2+/+ and CCR2-/- mice fed a chow or high fat 
diet for 6 weeks was quntified. In general, in the CCR2+/+ mice, HFD feeding 
decreased the percentage of eosinophils in all AT depots. In contrast, in the 
CCR2-/- mice HFD feeding for this short period of time increased the number of 
eosinophils as we previously reported (Figure 4.10C). The epididymal AT depot 
had the highest percentage and absolute number of eosinophils in both the 
CCR2+/+ and CCR2-/- mice, followed by the mesenteric and peri-renal depots, and 
lastly the subcutaneous AT depot (Epidydimal > Mesenteric = Peri-Renal > 
Subcutaneous) (Figure 4.20 A-D). This hierarchy is congruent with that of the 
most metabolically active AT depots, where the subcutaneous is the least 
metabolically active.  
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Figure 4.19 Flow cytometry analysis of AT eosinophils. Representative 
images of eosinophil quantification in A) CCR2+/+ and C) CCR2-/- mice gated on 
all live single cells. Represenstative images of Siglec-F isotype control for B) 
CCR2+/+ and C) CCR2-/- mice gated on all live single cells. 
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Figure 4.20. Quantification of eosinophils in AT depots. CCR2+/+ and CCR2-/- 
mice were fed a chow or high fat diet for 6 weeks. Quantification of the 
percentage of eosinophils in the A) epididymal depot, B) peri-renal depot, C) 
mesenteric depot and D) subcutaneous depot. Data are presented as mean ± 
SEM, n=5-6 per group.  
*P<0.05 Between genotypes, same diet. 
**P<0.01 Between genotypes, same diet. 
***P<0.001 Between genotypes, same diet. 
^P<0.05 Between diets, same genotype. 
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Eosinophils are Localized in the Interstitial Space of AT 
Epididymal AT sections were fixed and stained by immunofluorescence 
with an antibody against Siglec-F (Green), using DAPI (Blue) as a nuclei marker. 
Immunoflurorescence imaging of AT from CCR2+/+ and CCR2-/- mice showed that 
Siglec-F+ eosinophils are localized in the interstitial space between adipocytes 
and not in crown-like structures. Additionally, in support of the flow cytometry 
data we observe a larger number of eosinophils in AT from CCR2-/- mice in 
contrast to that of CCR2+/+ mice (Figure 4.21). 
 
Eosinophilia is Restricted to AT and Peritoneum 
 To determine if the observed eosinophilia in CCR2-/- mice was specific to 
AT and the peritoneum or if it was due global eosinophilia, we measured the 
eosinophil levels in circulation and bone marrow by flow cytometry. There were 
no differences in the bone marrow or blood levels of eosinophils between 
CCR2+/+ and CCR2-/- mice in either diet (Figure 4.22). Additionally, there were no 
differences in eosinophil levels in the liver or spleen of CCR2-/- mice when 
compared to the CCR2+/+ controls (data not shown). 
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Figure 4.21 AT Siglec-F Immunofluorescence. 
 Representative immunofluorescence images of epididymal AT sections from A) 
CCR2+/+ and B) CCR2-/- mice fed an HFD for 6 weeks; DAPI (Blue) and Siglec-F 
(Green). White arrows represent eosinophils.  
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Figure 4.22. Quantification of eosinophils in bone marrow and blood. 
CCR2+/+ and CCR2-/- mice were fed a chow or high fat diet for 6 weeks. 
Quantification of the percentage of eosinophils in the A) bone marrow and B) 
blood. Data are presented as mean ± SEM, n=4-6 per group. 
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Eosinophil Levels are Correlated with IL5 and Arg1 Expression in AT 
  Total RNA was purified from epididymal AT of CCR2+/+ and CCR2-/- mice 
and analyzed by real-time RT-PCR. Analysis of the expression of Il5, a cytokine 
known to increase eosinophil recruitment and local proliferation, showed a close 
correlation with the levels of eosinophils in this tissue (Figure 4.23A). 
Furthermore, assessment of mRNA expression of Arg1 showed an increase in 
the expression of this gene in the CCR2-/- mice when compared to their diet 
matched CCR2+/+ counterparts (Figure 4.23B). The increased expression of this 
M2 marker supports a regulation of alternative activation by the newly identified 
eosinophil population it AT.   
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Figure 4.23 Expression of Il5 and Arg1 in epididymal AT. Total RNA was 
isolated from epididymal AT of CCR2+/+ and CCR2-/- mice fed either a chow or 
high fat diet. Real-time RT-PCR expression of A) Il5 and B) Arg1. Data are 
presented as mean ± SEM, n=5-6 per group.  
*P<0.05 Between genotypes, same diet. 
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DISCUSSION 
CCR2-/- mice have been shown to have a modest reduction in 
macrophage recruitment to AT after extended periods of HFD feeding (35, 120).  
Given that the pool of circulating inflammatory monocytes is strikingly reduced in 
these mice (111) (Figure 4.2), inflammatory macrophage recruitment to AT 
should be correspondingly decreased. Thus, inflammation and IR in CCR2-/- mice 
is expected to be markedly decreased in comparison to CCR2+/+ controls upon 
placement on a HFD.  However, inflammation and inflammatory macrophage 
recruitment in CCR2-/- mice are only partially decreased and only after substantial 
obesity is attained (35, 120).  Our current studies explored mice with global and 
hematopoietic CCR2 deficiency at different periods of HFD feeding to investigate 
the mechanism involved in the delayed improvement in inflammation and insulin 
sensitivity.  
To understand processes that take place at earlier stages of obesity that 
could prevent improvements in inflammation and IR, we analyzed myeloid 
populations in AT of BM-CCR2-/-  and CCR2-/- mice and the control mice after 6, 
12 and 20 weeks of HFD by flow cytometry. Our data provide evidence for the 
accumulation of a unique CD11bloF4/80lo myeloid population in the AT of BM-
CCR2-/- (Figure 4.10 & 4.11) and CCR2-/- (Figure 4.12) mice after 6 and 12 weeks 
of HFD feeding. These CD11bloF4/80lo cells  are no longer detected in the AT of 
the BM-CCR2-/- and CCR2-/- mice after extended periods (> 20 weeks) of HFD 
feeding (Figure 4.10C, 4.12C & F). Our data suggest that the presence of the 
CD11bloF4/80lo cells is associated with the mechanism(s) for the delay in 
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improvements in inflammation and IR observed in these mice, and that 
substantial obesity and disappearance of the CD11bloF4/80lo cells are temporally 
correlated with these metabolic improvements. 
To determine the identity and phenotype of the novel CD11bloF4/80lo cells, 
we isolated RNA from these cells for gene expression characterization relative to 
that of the CD11bhiF4/80hi cells in Part I of this chapter. Altogether the expression 
data suggested that the CD11bloF4/80lo cells do not exhibit classical M1 or M2 
expression profiles, but instead have a unique inflammatory expression in 
contrast to that of CD11bhiF4/80hi macrophages. However, we later showed in 
Part II, that this was a mixed population of monocytic/granulocytic cells. 
 Chomarat et al. showed that during monocyte to macrophage 
differentiation there is an upregulation of CD115 (Csf1r) coupled by a 
downregulation of its ligand M-CSF (Csf1) (131). We measured the expression of 
both Csfr1 and Csf1, and found that in fact Csfr1 was downregulated while Csf1 
was upregulated in the CD11bloF4/80lo cells, suggesting that these cells might be  
in a monocytic transition stage.   To test this, we performed H&E staining of 
isolated cells and found that CD11bloF4/80lo cells have a monocytic/granulocytic 
morphology in contrast to the CD11bhiF4/80hi cells, which have a morphology 
characteristic of macrophages (Figure 4.13).  The expression profile and 
morphological analysis of the mixed CD11bloF4/80lo indicated that these are 
monocytic/granulocytic cells that accumulated in AT in the absence of CCR2. 
We also sought to investigate the presence of the CD11bloF4/80lo cells in 
wild type mice, independent of CCR2 deficiency. We isolated CD11bloF4/80lo and 
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CD11bhiF4/80hi macrophages from CCR2+/+ mice using identical gates as 
previously used for the CCR2-/- mice (Figure 4.13). Despite the absence of a 
discrete population under the CD11bloF4/80lo (P2) gate, we were able to isolate a 
relatively high number of cells. Gene expression analysis of key markers of 
CD11bloF4/80lo cells described previously, showed that CD11bloF4/80lo cells 
isolated from CCR2+/+ mice have identical gene expression patterns as those of 
the CCR2-/- mice (Figure 4.14). Additionally, H&E staining of isolated cells 
showed a similar monocytic/granulocytic morphology between the CCR2-/- and 
CCR2+/+ CD11bloF4/80lo cells. Moreover, we found that HFD feeding was not 
necessary for the accumulation of these cells in AT, as CD11bloF4/80lo cells were 
found in CD-fed CCR2+/+ and CCR2-/- mice (Figure 4.16). Next, we assessed 
whether these cells were found in other metabolically relevant tissues such as 
the liver. We did not observe their accumulation in this tissue; on the other hand, 
we did observe a decrease in recruited macrophages and no effects on resident 
Kupffer cells as recently described by Obstfeld et al. (132) (data not shown). 
These findings indicate that although CCR2 deficiency is not necessary for the 
recruitment of CD11bloF4/80lo cells to AT, it leads to the aberrant accumulation of 
these cells, which would otherwise only transiently be found in this AT depot.  
The identity of these cells was further studied in Part II of this chapter. 
After careful flow cytometric analysis, the peritoneal CD11bloF4/80lo cells were 
found to be CCR3+Siglec-F+, indicating unquestionably that they were 
eosinophils. When the immunophenotype of the AT CD11bloF4/80lo cells was 
assessed, these cells were CCR3-negative; however, they were Siglec-F positive 
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and had an eosinophil morphology. Altogether these data suggested that the 
CD11bloF4/80lo cells previously isolated in Part I are a combination of eosinophils 
and undifferentiated monocytes. Thus, the gene expression assessed previously 
is a reflection of the mixed population and not that of the homogeneous 
eosinophil population.  
Our study also tested whether the origin of the epididymal AT and 
peritoneal eosinophilia in CCR2-/- mice was caused by global eosinophilia, 
increased recruitment due to increased eotaxin expression, or local proliferation. 
Our data showed that eosinophilia was found in all white AT depots including: 
epididymal, peri-renal, mesenteric and subcutaneous. However, no eosinophilia 
was observed in the liver or spleens of CCR2-/- mice. The levels of eosinophils in 
the bone marrow and blood were also not different between CCR2+/+ and CCR2-/- 
mice. Furthermore, AT expression of the eosinophil chemoattractants: CCL11, 
CCL24 and CCL26, was not different between genotypes (data not shown). 
These data suggest that AT and peritoneal eosinophilia was not caused by global 
eosinophilia or increased recruitment, but likely by local proliferation of these 
cells. IL-5 is cytokine well known to induce local eosinophil proliferation (67, 133, 
134). In fact, mRNA expression of Il5 in epididymal AT closely correlated with the 
levels of eosinophils in this tissue. Furthermore, preliminary evidence indicates 
that the “M2” macrophages in this tissue are the main producers of this cytokine 
in AT. Eosinophils have been shown to sustain the “M2” activation of 
macrophages in the AT (49); thus, now we present evidence that “M2” cells are 
in turn probably inducing eosinophil local proliferation.  
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In conclusion, our data are the first to provide evidence for the aberrant 
accumulation of eosinophils in the AT of CCR2-/- mice, which is indirectly 
associated with improvements in inflammation and glucose tolerance. We found 
that eosinophils are also found in the AT of CCR2+/+ mice (albeit in lower 
numbers) and that HFD diet reduces the numbers of eosionophils in these mice. 
Our study has provided in vivo evidence for the role of CCR2 in macrophage 
polarization in AT, as well as the sustainment of the levels of eosinophils in this 
tissue.  Furthermore, we have highlighted the metabolic consequences of the 
aberrant accumulation of eosinophils in this tissue.  The discovery of eosinophilia 
in the AT of CCR2-/- mice has large implications on the use of CCR2 antagonism 
as a therapy for chronic inflammatory diseases, as it could lead to undesired side 
effects associated with eosinophilia (135, 136). Future and ongoing studies will 
investigate the specific roles of these cells in AT function as well as confirm the 
mechanism for their accumulation. 
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CHAPTER V 
 
COMPLEMENT FACTOR 5 DEFICIENCY LEADS TO SEVERE SYSTEMIC 
INSULIN RESISTSNCE, INDEPENDENT OF INFLAMMATION 
(Adapted from Gutierrez et al. Manuscript in Preparation, 2012) 
 
INTRODUCTION 
             The prevalence of adult and childhood obesity and associated co-
morbidities has significantly increased in the past three decades in the United 
States and other industrialized nations (137, 138). Obesity is associated with a 
state of chronic inflammation that leads to IR in AT, muscle and the liver (139-
141). IR is characterized by elevated circulating levels of pro-inflammatory 
cytokines, including tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), 
monocyte chemoattractant protein 1 (MCP-1), IL-1β and C-reactive protein (142). 
Systemic inflammation, IR and subsequent β cell failure are the primary causes 
of T2DM (9). 
The complement system is a vital component of the innate immune 
response (143). There are three known different complement activation pathways 
the classical, alternative, and lectin binding pathways. The classical pathway is 
activated by antigen-antibody complexes. The alternative pathway is initiated by 
surface molecules containing carbohydrates or lipids. The lectin-binding pathway 
is activated by the binding of mannose-binding lectin protein (58) to bacterial 
carbohydrate structures. High expression of complement components has been 
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shown in the omental AT of obese humans in comparison to lean individuals 
(81).  
 In this study, we examined the effects of deficiency in circulating C5 on 
systemic glucose tolerance and IR. Because C5a is a strong chemoattractant, we 
hypothesized that C5 deficiency would lead to decreased inflammation in AT and 
subsequent improved insulin sensitivity in a diet-induced obese mouse model. 
However, our studies show that C5 deficiency has no significant effects on AT 
and liver inflammation, but leads to severe glucose intolerance and systemic IR 
through the downregulation of the insulin receptor in liver, muscle and AT. These 
findings represent a novel role for a complement component in metabolism and 
introduce a novel mouse model for the study of IR and T2DM.  
  
106 
 
RESULTS 
Complement Expression in AT and Liver of High Fat Fed Mice 
C57BL/6 mice were fed either a: 10%, 45 % or 60% fat diet for 16 weeks. 
At the end of the study total mRNA was collected from AT and liver. Expression 
of complement factor 5 (Hc) was gradually increased in total AT as the 
percentage of fat in the diet increased; mice fed a 60% fat diet had a >10-fold 
increase in Hc expression when compared to mice fed a 10% diet (Figure 5.1A). 
Hc was unchanged in the liver with increasing diet fat percentage (Figure 1B).  
The expression of complement factor 3 (C3) and complement factor B, which are 
required for C5 cleavage, was unchanged in the AT and liver with HFD feeding 
(Figure 5.1 C-E). The expression of complement factor 6 (C6), which is required 
for the formation of the membrane attack complex with C5b and C7-9, was 
significantly reduced in both the AT (P<0.01) and liver (P<0.05) in the group fed a 
60% fat diet (Figure 5.1 F-G).  
Basal Parameters of C5D Mice 
 C5D and WT mice were weighed at 8 weeks of age before placement on a 
diet. C5D mice had a significantly lower body weight (P<0.0001) (Figure 5.2A). 
Body composition analysis showed that C5D mice had similar adiposity (Figure 
5.2B) to that of WT controls but lower lean mass (P<0.0001) (Figure 5.2C). 
Baseline fasting glucose measurement showed that C5D mice were mildly 
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hypoglycemic (P<0.001; Figure 5.2D); however, this was accompanied by a 40% 
increase in fasting insulin levels (P<0.001; Figure 5.2E). 
Weight Gain, Body Composition and Food Consumption 
C5D and WT mice were placed on a LFD (10% fat) or HFD (60% fat) for 
12 weeks. WT mice were significantly heavier than C5D mice after 5 weeks of 
HFD feeding (P<0.05). Mice on a LFD had similar end weight and weight gain 
rates (Figure 5.3A). Food consumption was not statistically different between 
groups; however, there was a trend towards higher Kcal/day consumption in both 
C5D LFD and HFD groups when compared to the WT mice in their respective 
diets (Figure 5.4). Body composition analysis showed the expected increase in 
adiposity in both the WT and C5D groups with HFD feeding after 6 (P<0.01; diet 
effect) and 12 weeks (P<0.001; diet effect) when compared to the LFD controls 
(Figure 5.3B & D).  The WT HFD fed mice had significantly higher lean mass 
(P<0.05, 6 weeks; P<0.001, 12 weeks; diet effect) than their LFD controls, while 
lean mass remained unchanged between HFD and LFD groups in the C5D mice 
(Figure 5.3C & E).  C5D mice had significantly lower adiposity after 6 (P<0.05; 
genotype effect) and 12 weeks (P<0.001; genotype effect) of HFD feeding when 
compared to HFD fed WT mice (Figure 5.3B& D). Total lean mass was not 
significantly different between HFD fed groups after either diet period (Figure 
5.3C & E). Both HFD groups had significantly heavier (P<0.001; diet effect) 
epididymal AT pads than their LFD counterparts (Figure 5.3F). Epididymal AT 
pad weight at the end of the study was 33% lower (P<0.001; genotype effect) for 
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the C5D HFD mice when compared to the WT HFD controls (Figure 5.3F). HFD 
fed WT mice had significantly higher liver mass (P<0.01; diet effect) than their 
LFD counterparts; conversely, the liver weight between LFD and HFD fed C5D 
mice was not different (Figure 5.3G).  HFD fed C5D mice had lower liver weights 
(P<0.01; genotype effect) than HFD WT mice (Figure 5.3G).  
Bone Marrow and Blood Leukocytes 
Bone marrow and blood leukocyte levels were measured by flow 
cytometry after 12 weeks on either a LFD or HFD. Cells were first gated on all 
DAPI-negative live cells. The cells were identified by their expression of the 
following extracellular markers: B cells (CD19+), neutrophils (CD11b+Ly6Ghi), 
Ly6Chi monocytes (CD11b+Ly6Chi), Ly6Clo monocytes (CD11b+Ly6Clo) and total 
T cells (CD3+). There were no significant differences in any of the tested 
leukocytes in the bone marrow or blood between C5D and WT mice fed either a 
LFD or HFD (Figure 5.5A-B). The proportion of CD4+ and CD8+ T cells in either 
the blood or bone marrow were also not different between genotype and/or diets 
(data not shown). 
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Figure 5.1 Complement expression in AT and liver during HFD feeding  
C57BL/6 mice were placed on either a 10%, 45% or 60% fat diet for 16 weeks; 
total mRNA expression was assessed by real-time RT-PCR. Hc (C5) mRNA 
expression in the A) AT and B) liver. Expression of C3 in: C) AT and D) liver. AT 
expression of: E) Fb and F) C6. G) Liver expression of C6.  Data are presented 
as mean ± SEM (n=4-7).   
*P<0.05; between 10% and 60%. 
**P<0.01; between 60% group and 45% and 10% group. 
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Figure 5.2 Basal parameters of WT and C5D mice 
 Eight week old B10.D2-Hc0 H2d H2-T18c/oSnJ (C5D) and C57BL/10SnJ (WT 
controls) were used in this study. Baseline: C) body weight; D) percent adiposity 
(total AT mass divided body weight); E) total lean mass; F) fasting glucose (5h 
morning fast) and G) Fasting Insulin (5h morning fast). Data are presented as 
mean ± SEM (n=26-27).  
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Figure 5.3 Metabolic Parameters of C5D mice.  
WT and C5D mice were placed on either a 10% or 60% fat diet for 12 weeks. A) 
Weight curve of WT and C5D mice in both HFD and LFD diet (n=12-14).  NMR-
measured B) Percent adiposity and C) Total lean mass after 6 weeks of feeding 
(n=12-14). NMR-measured D) Percent adiposity and E) Total lean mass after 12 
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weeks of feeding (n=11-14).  F) Epididymal fat pad weight and G) Liver weight at 
the end of the study (n=11-14). Data are presented as mean ± SEM.  
*P<0.05; between WT and C5D HFD groups (genotype effect). 
**P<0.01; between WT and C5D HFD groups (genotype effect). 
***P<0.001; between WT and C5D HFD groups (genotype effect). 
^P<0.05; diet effect 
^^P<0.01; diet effect 
^^^P<0.001; diet effect 
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Figure 5.4 Food consumption.  
Food intake was measured by calculating the daily difference between weight of 
initial food given and weight of food at the end of the week per mouse. Data are 
presented as Kcal/day per mouse. Data are presented as mean ± SEM (n=4-7). 
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Figure 5.5 Bone marrow and blood leukocytes.  
The levels of B cells, neutrophils, Ly6Chi monocytes, Ly6Clo monocytes and T 
cells from WT and C5D mice after 12 weeks on either a LFD or HFD diet were 
assessed by flow cytometry. Cells were first gated on the DAPI-negative live 
population. B cells were classified as all CD19(+) cells; Neutrophils 
CD11b(+)Ly6G(High); Ly6Chi monocytes CD11b(+)Ly6C(High); Ly6Clo 
monocytes CD11b(+)Ly6C(Low); T cells CD3ε(+).  A) Quantification of flow 
cytometry data in bone marrow of LFD and HFD fed WT and C5D mice. B) 
Quantification of leukocytes in the blood of LFD and HFD fed WT and C5D mice. 
Data are presented as mean ± SEM (n=2-5). 
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AT Inflammation and Histology 
 AT inflammation was assessed by measuring the mRNA expression of 
several inflammatory and immune cell markers in all groups after 12 weeks of 
HFD feeding.(19, 24, 139) Expression of the cytokines Il1β, Tnf, Ccl2 and Il10 
showed the expected increase with HFD feeding in both C5D and WT mice when 
compared to LFD controls; however statistical significance was only reached for 
Tnf (P<0.001) and Ccl2 (P<0.01) in both genotypes, and  Il10 in the WT group 
(P<0.00; Figure 5.6A-D). Comparison of both HFD groups showed that C5D mice 
had similar Il1β and Tnf expression, a trend towards a reduction in Ccl2 
expression, and a significant reduction in Il10 expression (P<0.05) (Figure 5.6A-
D). Analysis of Emr1 (F4/80) expression, a well established AT macrophage 
marker (24), showed a significant increase in macrophage content in the WT 
HFD mice when compared to the LFD counterparts (P<0.001; diet effect); this 
increase in Emr1 expression was attenuated in the C5D mice (Figure 5.6E). 
Expression of the T cell marker Cd3ε was not different between groups (Figure 
5.6F). Thus, contrary to our hypothesis, AT inflammation was not significantly 
affected by C5 deficiency. 
 The C57BL/6, B10.D2-Hc0 H2d H2-T18c/oSnJ (C5D) mice are able to 
transcribe Hc mRNA and synthesize the C5 protein; however, due to a 2-base 
pair deletion at the 5’-exon, they are not able to secrete this protein (144-146). 
We analyzed the effects of HFD feeding on Hc gene expression. Similar to what 
was observed in C57BL/6 mice, HFD feeding increased Hc expression in the WT 
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(C57BL/10) mice (P<0.001); this increase was completely attenuated in the C5D 
mice (Figure 5.6G). There was a small increase in the expression of C3 in HFD 
fed WT mice compared to WT LFD fed mice (P<0.05) and a trend towards an 
increase in C3 expression in C5D HFD fed mice when compared to their LFD 
counterparts (Figure 5.6H).  
 AT sections were stained with H&E and analyzed by light microscopy. 
Representative 100X and 400X images are shown (Figures 5.6I-N).  The 
adipocyte diameter was increased in both HFD groups in comparison to their 
LFD counterparts (P<0.001). In addition, there was a significant decrease in 
adipocyte size in the C5D HFD group when compared to the WT HFD group 
(P<0.05) (Figure 5.6O). There was a trend towards a decrease in the number of 
crown-like structures in the HFD fed C5D mice when compared to the HFD WT 
mice (Figure 5.6P). 
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Figure 5.6 Adipose tissue inflammation and histology.  
AT was collected at the end of the study for mRNA expression and histology 
analyses. Relative mRNA expression of: A) Il1β, B) Tnf, C) Ccl2, D) Il10, E) 
Emr1, F) Cd3ε, G) Hc and H) C3. Data are presented as mean ± SEM (n=11-13).  
Fixed AT sections were stained using H&E. Representative images of I) WT LFD 
mice (100X), J) WT HFD mice (100X) and K) WT HFD mice (400X).  
Representative images of: L) C5D LFD mice (100X), M) C5D HFD mice (100X) 
and N) C5D HFD mice (400X). O) Adipocyte diameter in micrometers (All 
adipocytes in 100X field counted; n=4) P) Number of crown-like structures per 
field. Data are presented as Mean ± SEM (n=3-4).  
*P<0.05; between WT and C5D HFD groups (genotype effect). 
**P<0.01; between WT and C5D HFD groups (genotype effect). 
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^P<0.05; diet effect 
^^P<0.01; diet effect 
^^^P<0.001; diet effect 
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Hepatic Inflammation and Function 
The majority of complement proteins are synthesized in the liver, including 
most of the circulating C5 (61). Thus it is important to evaluate the effects of C5 
deficiency on liver inflammation and function. Total liver RNA was isolated and 
mRNA expression levels were analyzed by real-time RT-PCR. Expression of the 
inflammatory cytokines Il1β and Tnf was not affected by the genotype or diet of 
the mice (Figure 5.7A-B). Ccl2 expression was significantly increased (P<0.05; 
genotype effect) in C5D HFD mice when compared to WT HFD mice; there was 
a trend toward an increase in the expression of this gene in the C5D LFD group 
in comparison to the WT LFD group (Figure 5.7C). Expression of Il10 was 
increased (P<0.05; diet effect) in the WT HFD group when compared to the WT 
LFD group and this increase was attenuated in the C5D HFD group (Figure 
5.7D). The expression of the macrophage marker Emr1 and the T cell marker 
Cd3ε was unchanged between genotypes and diets (Figure 5.7E-F).  
 Hepatocytes are the main producers of C5 in the body. In fact, the levels 
of Hc transcript in the livers of WT LFD mice are 4700-fold higher than the levels 
of this transcript in total AT of the same mice. The expression of the Hc gene was 
significantly decreased (P<0.001; genotype effect) in both LFD and HFD C5D 
mice in comparison to their WT counterparts, indicating a downregulation of this 
transcript upon the lack of C5 protein secretion (Figure 5.7G). Conversely, the 
transcription of C3 was unaffected by C5 deficiency, and similar to the 
expression in the C57BL/6 mice, it was unchanged by HFD feeding (Figure 
5.7H).  
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 Frozen liver sections were stained with H&E and images captured by light 
microscopy. Representative 100X images are shown (Figure 5.7I-L). These 
images showed no gross morphological differences between genotypes and 
diets. Additionally, no overt differences in immune cell infiltration were observed. 
 In view of the fact that C5 is synthesized at high levels in the hepatocytes 
of C5D mice, but not secreted (144-146), this condition could lead to 
endoplasmic reticulum stress (ER stress) and/or oxidative stress and ER stress-
induced inflammation.  We tested several markers of ER stress, oxidative stress 
and inflammation by Western blot analysis. Contrary to what was expected, the 
protein levels of the ER stress marker IRE-1α were decreased (P=0.0553; 
genotype effect) in C5D LFD mice when compared to WT LFD mice. The protein 
levels of the ER stress marker BiP, the phosphorylation levels of the 
inflammatory mediator JNK1/2 and the protein levels of the oxidative stress 
marker SOD-2 were unchanged between both LFD groups (Figure 5.8A & C). 
Similarly to the LFD groups, total IRE-1α expression was significantly (P<0.05) 
decreased in the C5D HFD group when compared to the WT HFD group. 
Additionally, levels of BiP, phospho-JNK1/2 and SOD-2 were unchanged in the 
C5D HFD group when compared to the WT HFD mice (Figure 5.8B & D). 
 Liver triglyceride content was measured by gas chromatography mass 
spectrometry. Hepatic triglyceride content increased in WT mice with HFD diet 
feeding (P<0.001; diet effect). However, this increase in triglycerides with HFD 
feeding was attenuated in C5D mice (Figure 5.9A). In fact, total triglyceride 
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content in the C5D HFD group was 70% lower in comparison to the WT HFD 
group (P<0.001; genotype effect). In support of the mass spectrometry data, Oil 
Red O staining of liver sections showed a marked increase in neutral lipid 
staining in WT HFD mice in comparison to LFD fed WT mice (Figure 5.9C). In 
contrast, the liver images from C5D HFD fed mice (Figure 5.9E) show an 
attenuation in the accumulation of neutral lipid when compared to C5D LFD fed 
mice and WT HFD fed mice (Figure 5.9E). Hepatic lipid content is regulated by 
lipid and glucose metabolism in the liver. We assessed the gene expression of 
genes associated with gluconeogenesis, glycolysis, fatty acid synthesis and fatty 
acid oxidation. The expression of the gluconeogenic protein glucose-6-
phosphatase was paradoxically decreased with HFD feeding on the WT mice 
(P<0.01; diet effect); however, there was no diet effect found in the C5D mice 
(Figure 5.9F).  Conversely, the expression of phosphoeno pyruvate 
carboxykinase another gluconeogenic enzyme was increased with HFD feeding 
in C5D mice (P<0.05; diet effect) and there was a trend towards an increase in 
HFD fed WT mice in comparison to LFD fed WT mice (Figure 5.9G). Expression 
of the hepatic glycolytic enzyme glucokinase was not affected by the genotype or 
diet of the mice (Figure 5.9H). Acetyl CoA carboxylase, an enzyme important in 
fatty acid synthesis, was decreased with HFD feeding in both WT (P<0.001; diet 
effect) and C5D (P<0.001; diet effect) mice (Figure 5.9I). In contrast there was an 
increase in the expression of the β oxidation enzyme, peroxisomal acyl-
coenzyme A oxidase, with HFD feeding (P<0.001; diet effect); this increase was 
attenuated in HFD fed C5D mice (Figure 5.9J).  
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Figure 5.7 Hepatic inflammation and histology. 
 Liver sections were collected at the end of the study and used for mRNA 
expression and histology analyses. Relative mRNA expression of: A) Il1β, B) Tnf, 
C) Ccl2, D) Il10, E) Emr1, F) Cd3ε, G) Hc and H) C3.  Data are presented as 
mean ± SEM (n=11-13). Frozen liver sections were stained by H & E. 
Representative (100X) images of: I) WT LFD mice, and J) WT HFD mice. 
Representative images of: K) C5D LFD mice and L) C5D HFD mice. 
*P<0.05; between WT and C5D HFD groups (genotype effect). 
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***P<0.001; between WT and C5D HFD groups (genotype effect). 
+++P<0.001; between WT and C5D LFD groups (genotype effect). 
^P<0.05; diet effect 
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Figure 5.8  Hepatic ER- and oxidative-stress markers.  
Protein lysates were prepared from the livers of the mice. Western blot analysis 
was conducted to measure the protein expression of IRE-1α, BiP, phospho-JNK, 
and SOD2 in A) LFD and B) HFD WT and C5D mice. β-actin was used as a 
protein loading control. Quantification of IRE-1α, BiP, phospho-JNK, and SOD2 
protein expression in C) LFD and D) HFD WT and C5D mice.  Data are 
presented as mean ± SEM (n=8). 
*P<0.05; between WT and C5D HFD groups (genotype effect). 
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 Figure 5.9 Hepatic lipid and glucose metabolism.  
Total liver triglyceride content in LFD and HFD fed WT and C5D mice was 
assessed by mass spectrometry. A) Levels of triglyceride in WT and C5D mice 
presented as micrograms of triglyceride per milligram of liver (n=4-6). Frozen 
liver sections were stained with Oil-Red-O, which stains all neutral lipids. B-E) 
Representative 100X images of Oil-Red-O stained liver sections of LFD and HFD 
fed WT and C5D mice. Liver sections were collected at the end of the study and 
used for mRNA expression analysis. Relative mRNA expression of: F) G6pc, G) 
Pck1, H) Gck, I) Acacb, J) Acox1. Data are presented as mean ± SEM (n=11-13). 
***P<0.001; between WT and C5D HFD groups (genotype effect). 
^P<0.05; diet effect 
^^P<0.01; diet effect 
^^^P<0.001; diet effect 
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C5D Mice Have Severe Glucose Intolerance and Insulin Resistance 
 It is well established that HFD feeding leads to glucose intolerance and IR 
(36). A glucose tolerance test (GTT) was performed on the mice 6 weeks after 
LFD or HFD feeding. The WT HFD mice (black solid line & square) were 
significantly more glucose intolerant than the WT LFD group (P<0.05; diet effect) 
(red dashed line & solid triangle) at 30 minutes post-glucose injection and there 
was a trend towards more glucose intolerance in the WT HFD group at every 
other time point. The C5D HFD group (green line & open square) had 
significantly more glucose intolerance than the C5D LFD group (blue dashed line 
& open triangle) after 60 (P<0.05; diet effect), 90 (P<0.001; diet effect) and 120 
(P<0.001; diet effect) minutes post injection; thus demonstrating a diet effect on 
glucose intolerance in C5D mice. Furthermore, when comparing the WT and 
C5D mice, C5 deficiency led to severe glucose intolerance in both the HFD 
(P<0.05, 45 min; P<0.001 60-120 min; genotype effect) and LFD mice (P<0.01, 
45, 90 min; P<0.05, 45 min; genotype effect) (Figure 5.10A). A second GTT was 
performed after 12 weeks of LFD or HFD feeding. As expected due to longer 
time on HFD, a more severe diet effect was observed between the HFD and LFD 
fed WT (P<0.05; diet effect) and C5D mice (P<0.05; diet effect). Additionally, 
there was a strong genotype effect; C5D HFD fed mice were significantly more 
glucose intolerant than WT HFD mice (P<0.01 30 min; P<0.001 45-150 min). The 
genotype effect was also present on the LFD fed mice, where the C5D mice were 
significantly (P<0.01; 45-90 min) more glucose intolerant than their WT 
counterparts (Figure 5.10B). 
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 To investigate if the observed glucose intolerance was due to an insulin 
secretion defect by the β cells or due to systemic IR, fasting insulin levels were 
measured by ELISA.  After 6 weeks on the diet, HFD fed C5D mice had 83% 
more circulating insulin than LFD C5D mice (P<0.01; diet effect) (Figure 5.10C). 
High fat fed C5D mice had 1.6-fold (P<0.001; genotype effect) more circulating 
insulin than the HFD fed WT mice (Figure 5.10C). At the 12 week time point 
there was a 1.25-fold (P<0.01; genotype effect) increase in fasting insulin in the 
C5D LFD group when compared to the WT LFD group (P<0.01; genotype effect). 
Both the C5D and WT HFD groups had significantly higher fasting insulin than 
the corresponding LFD groups (P<0.05; diet effect; Figure 5.10D).  
To further analyze islet physiology and function in these mice we 
performed H&E and insulin immunohistochemistry on frozen pancreata sections. 
H&E staining images showed no overt defects on the islets of either genotype 
and/or diet, there were also no signs of insulitis or pancreatitis (data not shown). 
Insulin immunohistochemistry images showed no obvious differences in islet 
morphology; additionally, we observed an overall increase in islet size with HFD 
feeding, consistent with the fasting insulin levels observed after 12 weeks of HFD 
feeding. Representative insulin immunohistochemistry images are shown in 
Figure 5.10E-H.  
 The WT controls utilized throughout most of this study are on a C57BL/10 
background with a MHCIIb haplotype. The C5D mice are also on C57BL/10 
background, but have a MHCIId haplotype. To test whether the phenotype 
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observed in these mice was due to the deficiency in C5 and not the different 
haplotypes, we performed a separate study to measure the glucose tolerance of 
C5D MHCIId, WT MHCIIb and WT MHCIId mice. Similarly to the previous study, 
after 6 and 12 weeks of HFD feeding, C5D mice were more glucose intolerant 
than WT MHCIIb mice, which were more glucose intolerant than WT MHCIId  mice 
(C5D > MHCIIb > MHCI (Figure 5.11A-B). Thus, we can rule out the haplotype 
difference as being responsible for the insulin resistant phenotype noted in the 
C5D mice.  
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Figure 5.10 Glucose tolerance, insulin resistance and islet histology.  
After a 5h fast mice were injected with 1 g of dextrose per kg of lean mass, and 
glucose clearance was tracked for 120 or 150 min. A) Glucose tolerance test 
curve after 6 weeks of diet feeding for LFD and HFD fed WT and C5D mice (n=9-
13). B) Glucose tolerance test curve after 12 weeks of diet feeding for LFD and 
HFD fed WT and C5D mice (n=11-14). Fasting insulin levels after a 5h fast 
following C) 6 weeks (n=10-14) and D) 12 weeks of HFD feeding (n=10-13).  E-
H) Representative 100X images of pancreas sections stained by 
immunohistochemistry using an antibody against insulin. Staining performed in 
the  Vanderbilt IHC core. 
*P<0.05; between WT and C5D HFD groups (genotype effect). 
**P<0.01; between WT and C5D HFD groups (genotype effect). 
***P<0.001; between WT and C5D HFD groups (genotype effect). 
+P<0.05; between WT and C5D LFD groups (genotype effect). 
++P<0.01; between WT and C5D LFD groups (genotype effect). 
+++P<0.001; between WT and C5D LFD groups (genotype effect). 
^P<0.05; diet effect 
^^P<0.01; diet effect 
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Figure 5.11 Glucose tolerance tests for the WT MHCIIb, WT MHCIId and C5D 
MHCIId study.  
After a 5h fast mice were injected with 1 g of dextrose per kg of lean mass, and 
glucose clearance was tracked for 120 min. A) Glucose tolerance test curve after 
6 weeks of HFD feeding for WT MHCIIb, WT MHCIId and C5D MHCIId mice. B) 
Glucose tolerance test curve after 12 weeks of HFD feeding for WT MHCIIb, WT 
MHCIId and C5D MHCIId mice. Data are presented as mean ± SEM (n=3-4). 
*P<0.05; between WT MHCIId and C5D MHCIId HFD groups. 
**P<0.01; between WT MHCIId and C5D MHCIId HFD groups. 
***P<0.001; between WT MHCIId and C5D MHCIId HFD groups. 
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Mechanism(s) for Insulin Resistance 
 Given the absence of a genotype effect on AT and hepatic inflammation, 
we sought to find inflammation-independent mechanisms for the observed IR in 
the C5D mice. Analysis of the mRNA expression of the insulin receptor (Insr) 
showed a ~ 50% decrease (P<0.001; genotype effect) in Insr expression in both 
the liver and AT of C5D mice fed a low or high fat diet (Figure 5.12A-B).  The 
expression of other molecular components that modulate insulin signaling was 
also assessed. There were no genotype or diet effects on the hepatic mRNA 
expression of insulin-like growth factor 1 receptor (Igf1r), the insulin-like growth 
factor 1 (Igf1), Irs1, Irs2 or the insulin-like growth factor binding protein 3 (Igfbp3) 
(Figure 5.13). Western blot analysis using an antibody against the β subunit of 
the INSR showed a >60% decrease (P<0.01; genotype effect) in the mature 
active form of this subunit in LFD fed C5D mice, in the liver (Figure 5.14A), AT 
(Figure 5.14C) and skeletal muscle when compared to the WT LFD group (Figure 
5.14). Similar results were obtained for the HFD fed groups (Figure 5.15). 
 Analysis of AKT phosphorylation at serine 473, which is a mediator 
downstream of INSR signaling, showed increased phosphorylation in the livers of 
WT LFD mice 15 min after a bolus injection of 1.0 U of insulin per kilogram of 
lean mass, when compared to mice injected with saline (P<0.001). Interestingly, 
this increase in AKT phosphorylation was blunted in C5D LFD mice (Figure 
5.14B). Similar to the liver, AKT phophorylation in AT was increased in WT LFD 
mice after insulin injection, and this increase in phosphorylation was blunted in 
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the C5D LFD mice (P<0.01) (Figure 5.14D). AKT phosphorylation in the liver and 
AT after insulin injection was blunted in both HFD groups; however, the WT HFD 
mice had a trend towards increased phosphorylation when injected with insulin, 
while AKT phosphorylation remained virtually unchanged in the C5D group after 
the injection (Figure 5.15B & D). Unlike the liver and AT, AKT phosphorylation in 
the skeletal muscle was not disrupted by C5 deficiency (Figure 5.14F & Figure 
5.15F), despite the observed decrease in INSR β expression.  
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Figure 5.12 Insulin receptor mRNA expression in the liver and AT. 
  Total RNA was collected from liver and AT at the end of the study and used for 
real-time RT-PCR analysis. Expression of Insr in the: A) Liver and B) AT after 12 
weeks of LFD or HFD feeding in WT and C5D mice. Data are presented as mean 
± SEM (n=11-13). 
***P<0.001; between WT and C5D HFD groups (genotype effect). 
++P<0.01; between WT and C5D LFD groups (genotype effect). 
+++P<0.001; between WT and C5D LFD groups (genotype effect). 
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Figure 5.13  Gene expression of modulators of insulin signaling in the liver.  
Liver sections were collected at the end of the study and used for mRNA 
expression analysis. Relative mRNA expression of: A) Igf1r, B) Igf1, C) Irs1, D) 
Irs2, E) Igfbp3. Data are presented as mean ± SEM (n=11-13).                                                                                                                                                                                                                                                          
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Figure 5.14  Levels of insulin receptor protein and insulin signaling in liver, 
AT and muscle of LFD fed WT and C5D mice.  
Protein lysates were collected from liver, AT, and muscle of LFD fed WT and 
C5D mice at the end of the study, and protein expression and phosphorylation 
levels assessed by Western blot analysis. A) INSR-β expression (n=8) and B) 
Phopho-AKT levels in the liver (n=2-6). C) INSR-β expression (n=8) and D) 
Phopho-AKT levels in the AT (n=2-6).  E) INSR-β expression (n=8) and F) 
Phopho-AKT levels in the muscle (n=2-6). Data are presented as mean ± SEM.  
*P<0.05; between WT and C5D LFD groups (genotype effect). 
**P<0.01; between WT and C5D LFD groups (genotype effect). 
***P<0.001; between WT and C5D LFD groups (genotype effect). 
^P<0.05 between saline injected and insulin injected LFD WT and C5D mice. 
^P<0.05 between saline injected and insulin injected LFD WT and C5D mice. 
^^^P<0.05 between saline injected and insulin injected LFD WT and C5D mice. 
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Figure 5.15 Levels of insulin receptor protein and insulin signaling in liver, 
AT and muscle of HFD fed WT and C5D mice.  
Protein lysates were collected from liver, AT and muscle of HFD fed WT and 
C5D mice at the end of the study; protein expression and phosphorylation levels 
were assessed by Western blot analysis. A) INSR-β expression (n=8) and B) 
Phopho-AKT levels in the liver (n=2-6). C) INSR-β expression (n=8) and D) 
Phopho-AKT levels in the AT (n=2-6).  E) INSR-β expression (n=8) and F) 
Phopho-AKT levels in the muscle (n=2-6). Data are presented as mean ± SEM.  
**P<0.01; between WT and C5D HFD groups (genotype effect). 
^P<0.05 between saline injected and insulin injected HFD WT and C5D mice. 
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The Pro-INSR in C5D Mice Has a Differential Glycosylation State 
 In view of the fact that the decrease in mature INSR levels was greater 
than that observed in the Insr message, we assessed whether there was a defect 
in post-transcriptional processing of the INSR. We used an antibody against the 
β subunit of the INSR, which recognizes both the mature β subunit and the 
precursor for the insulin receptor (pro-INSR). Two different lanes of the pro-INSR 
were detected for the liver (Figure 5.16A) and AT (Figure 5.16B) of C5D mice at 
~ 190 and 180 KDa, while only the 190 KDa lane was detected in the WT mice. 
In contrast, the skeletal muscle of the C5D mice have, only one pro-INSR lane 
(Figure 5.16C), similarly to the WT mice. 
 Incubation of liver protein lysates from C5D and WT mice with N-
glycosidase F (PNGase F), leads to the formation of a single 170 KDa sized 
protein, which corresponds to the non-glycosylated pro-INRS molecular weight, 
and the disappearance of the 190 and 180 KDa lanes in the C5D mice (Figure 
5.16D). This indicated that C5D mice have differential glycosylation of the pro-
INSR protein in comparison to the WT mice.  
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Figure 5.16 Differential glycosylation of the INSR of C5D mice.  
Western blot analysis of the precursor of INSR (pro-INSR) in the: A) liver, B) AT, 
and C) muscle (190 KDa lane is fully glycosylated pro-INSR; 180 KDa lane is 
partially glycosylated pro-INSR). An F-glycosidase reaction of liver protein 
samples from LFD WT and C5D mice was performed. D) Western blot analysis 
of pro-INSR in protein samples of LFD WT and C5D mice incubated with (+) or 
without (-) PNGase F (190 KDa: fully glycosidated; 170 KDa: no glycosylation).  
(n=4). 
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DISCUSSION 
The complement system, an important component of the innate immune 
system, is activated in response to pathogen invasion and in several diseases. 
Several roles for the cleavage products of C5 during infection have been 
identified, including: recruitment and activation of inflammatory cells, induction of 
phagocytosis, oxidative burst, release of granule enzymes, cell lysis, and 
hematopoiesis (61).  Furthermore, C5 has been shown to play important non-
inflammatory homeostatic functions such as promotion of tissue regeneration and 
angiogenesis (147), stem cell mobilization (148), development of the central 
nervous system and embryogenesis (149). However, to this date, no studies 
have evaluated the effects of C5 deficiency on either normal metabolism or 
obesity. Our studies showed that C5 plays a vital inflammation-independent role 
in metabolism, and its deficiency leads to the dysregulation of glucose 
metabolism by disrupting insulin signaling in both the lean and obese states.  
The complement system, specifically the cleavage products of C5, has 
been shown to play a role in stem cell mobilization from the bone marrow into the 
circulation (148, 150). Leukocyte mobilization from the bone marrow into the 
circulation and into tissues is an important factor in tissue inflammation and its 
disruption leads to changes in the inflammatory sate of the target tissue. Such is 
the case of CCR2 deficiency, where blunted egress of Ly6Chi monocytes leads to 
changes in the inflammatory state of AT (35,37,111). Therefore, it was important 
to examine if C5 deficiency affected the levels of leukocytes that could impact 
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inflammation and thus metabolism. We analyzed the levels of bone marrow and 
blood leukocytes by flow cytometric analysis and found no overt differences in 
the levels of B cells, neutrophils, monocytes or T cells in either the bone marrow 
or blood of C5D mice when compared to WT mice, regardless of the diet (Figure 
5.5). Thus any changes observed in the metabolic state of these mice were 
unlikely to be due to differences in leukocyte populations. 
Recently the immune system has been shown to play a pivotal role in 
metabolism, especially in the obese state (141). However, the role of the immune 
system in immunometabolism has always been associated with 
regulating/causing a heightened state of inflammation observed during obesity 
(139). Of vast importance is the presence of macrophages and other immune 
cells in AT and their role in their regulation of AT function and insulin sensitivity 
(25, 54). The current study was designed with the hypothesis that C5 deficiency 
would lead to decreased AT inflammation and thus improved insulin sensitivity in 
the obese state. However, our study fortuitously led to finding a seminal 
inflammation-independent role of a component of the complement system on 
glucose metabolism. 
When placed on an HFD, C5D mice showed resistance towards weight 
gain and after 12 weeks of HFD feeding were on average 5 grams smaller than 
HFD fed WT mice (Figure 5.3A). This difference in total mass was accounted for 
by a significant decrease in AT mass (Figure 5.3D & F). Lower fat mass by itself, 
in most cases, (except for cases of lipodystrophy) leads to decreased leukocyte 
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infiltration of AT and decreased inflammation, leading to improvements in insulin 
sensitivity. In fact, C5D mice had a mild decrease in AT expression of 
inflammatory and macrophage markers and a trend towards a reduction of crown 
like structures in comparison to their diet-matched WT counterparts (Figure 5.6). 
Thus, C5D directly through modulating the immune system or indirectly by 
affecting weight gain led to decreased AT inflammation. However, in this case, 
reduced AT inflammation did not lead to systemic improvements in IR as will be 
discussed below.  
Total liver RNA extracts in this study had 4.7X103 more copies of Hc (C5) 
transcript than the same quantity of total RNA in AT. In view of the fact that C5 in 
the B10.D2-Hc0 H2d H2-T18c/oSnJ mice is transcribed but not secreted because 
of a two-base pair deletion in exon 1 of this gene, generating an early stop codon 
at the 5’ end of the transcript (146), accumulation of C5 in the hepatic ER could 
lead to ER-stress-induced inflammation and deleterious effects on metabolism. 
To assess this, we first contrasted C5 expression in C5D mice to that of diet-
matched WT mice; C5D mice had a 70% reduction in the expression of C5 in 
both diets (Figure 5.7G). Assessment of ER and oxidative stress showed either 
no effect or a reduction in markers of both processes (Figure 5.8). Additionally, 
evaluation of the inflammatory state of the liver by mRNA expression of 
inflammatory cytokines, leukocyte markers or levels of phosphorylation of JNK 
showed no significant differences in inflammation between C5D and WT mice in 
either diet (Figures 5.7-5.8). Evaluation of H & E stained liver sections showed no 
overt differences or abnormal immune infiltration. Furthermore, the gene 
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expression of macrophage (Emr1) and T cell (Cd3ε) markers showed no 
differences in the levels of these cells between WT and C5D mice. Altogether 
these data indicates that any differences in hepatic insulin sensitivity are likely 
independent of inflammation and/or ER stress.  
C5D mice showed marked glucose intolerance and IR when fed a LFD 
and this was worsened when mice were fed an HFD. C5a has been shown to 
have an anti-inflammatory effect in the pancreas and its deficiency led to 
worsened acute pancreatitis (151). To rule out pancreatitis and/or insulitis as the 
cause for glucose intolerance, pancreata sections were analyzed by H&E 
staining and insulin immunohistochemistry; there was no insulitis or pancreatitis 
observed in the pancreata of C5D mice, additionally the islet size and 
architecture appeared normal. In support of the histology data, the levels of 
fasting plasma insulin suggested that the observed glucose intolerance was 
caused by systemic IR.  
A more in depth analysis of insulin signaling showed decreased AKT 
phosphorylation after a bolus injection of insulin in the livers and AT of C5D mice 
when compared to WT mice (Figure 5.14). However, AKT signaling was not 
affected in the muscle of the C5D mice. This result is similar to that obtained for 
the muscle-specific Insr knockout (MIRKO), mouse where signaling downstream 
of IGF-1R was shown to play an important compensatory role in the muscle 
(152). Additionally, the metabolic phenotype observed in the C5D mice was 
congruent with that found in other tissue-specific Insr knockout models. For 
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example, the AT-specific Insr knockout (FIRKO) (153)  mice have lower fat mass 
and decreased total body triglyceride content, both of which were observed in the 
C5D mice (Figure 5.3D & Supp. Figure 5.9A). The liver-specific knock out model 
(LIRKO) (154) develops severe insulin resistance and hyperinsulinemia, both of 
these phenotypes were observed in the C5D mice (Figure 5.14B & Figure 5.10C-
D). Altogether, these data indicate that C5D mice have resistance to insulin 
signaling in all metabolic tissues except the muscle, similar to the insulin receptor 
tissue specific knockout mouse models.  
In support of the systemic insulin sensitivity data and tissue specific IR, 
defective expression levels and processing of the INSR were found in C5D mice. 
First, expression of Insr mRNA was found to be decreased by >50% in both the 
liver and AT of C5D mice in comparison to WT mice (Figure 5.12A-B). Second, 
analysis of the mature protein INSR-β by Western Blot showed a 70% decrease 
in the liver and a >50% decrease in AT and muscle (Figure 5.14 & 5.15).  
Additionally, differential glycosylation was observed in the pro-INSR molecule in 
the AT and livers of C5D mice. C5D mice, rather than having 100% of the pro-
INSR molecules fully glycosylated at a molecular weight of 190 KDa, had two 
different bands at 190 and 180 KDa, indicating differential or incomplete 
glycosylation (Figure 5.15A-B). A glycosidase assay using N-Glycosidase F 
showed that in fact the two different molecular weight bands were a result of 
differential glycosylation between the WT and C5D mice. The mechanism by 
which C5 deficiency led to differential glycosylation and decreased INSR 
expression remains unknown. However, we are actively investigating a direct 
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effect of C5a on Insr expression and INSR glycosylation, as well as the effects of 
C5a antagonism on the same processes.  
A second hypothesis for the observed phenotype is that C5a can act as a 
hypoglycemic hormone that supplements the activity of insulin in metabolism. 
There is strong evidence for a function of C5a as potent hypoglycemic molecule 
in neutrophils and eosinophils (155, 156); this increase in glucose uptake has 
been shown to be glucose transporter mediated. Furthermore, mice deficient in 
C5L2, one of the receptors for C5a, have an almost identical phenotype to that 
observed for C5D mice in the current study (157, 158). Therefore, we are 
investigating a potential role of C5a as a hypoglycemic hormone in metabolic 
tissues, which if found, would explain the metabolic phenotype of the C5D mice. 
In conclusion our studies for the first time have shown a role of the 
complement system in non-inflammatory modulation of metabolism. C5D mice 
have severe glucose intolerance and systemic IR that is independent of 
inflammation and/or obesity. Systemic IR is caused by defective INSR 
processing that leads to decreased Insr mRNA expression and decreased 
mature INSR levels in all metabolic tissues. Additionally, we are currently testing 
whether C5a acts as a hypoglycemic hormone in metabolic tissues. Whether or 
not a direct effect of C5a and C5 deficiency on glucose uptake or INSR 
expression/processing is found in future studies, we have now established a 
novel model of T2DM, that can become a useful tool for the study of drugs and 
therapies, as well as the study of cardiovascular complications associated with 
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this disease. Unlike global INSR knockout mouse models, these mice are viable, 
yet they have significant decreases in the expression of this receptor and insulin 
signaling at metabolic tissues.  
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CHAPTER VI 
 
SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
The incidence of obesity and T2DM is on the rise in the United Sates and 
other industrialized nations. The World Health Organization estimated that more 
than 1.5 billion adults worldwide were overweight and 500 million were clinically 
obese in the year 2008 (159).  Obesity has been shown to be associated with 
many diseases including several cancers and sleep apnea; however, the impact 
of obesity in most tissues involved in nutrient metabolism is due to its association 
with IR and T2DM.  IR, defined as the decrease sensitivity in the liver, AT and 
muscle to increasing levels of insulin, has been shown to be the link between 
obesity and T2DM. Over the past decade a search towards a unifying 
mechanism that explains the association between obesity, IR and T2DM has 
revealed a close association between caloric excess and chronic inflammation. 
This has led to the redefinition of obesity as an inflammatory disease, termed 
“metainflammation” (50), and has created the new field  of Immunometabolism 
that aims to study the effects of the immune system on metabolism (141). 
“Metainflammation”, or the chronic inflammation associated with obesity, is 
distinct from the “classical” inflammation which is a coordinated function of the 
immune system in response to a harmful stimulus or injury. This classical 
inflammation leads to the elimination of invading pathogens and the repair and 
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restoration of tissue homeostasis. The chronic inflammation associated with 
obesity involves many of the same mediators as “classical” acute inflammation, 
but rather than leading to tissue repair, it leads to tissue deterioration (50). 
Chronic inflammation associated with obesity involves all three organs 
associated with glucose metabolism and IR, liver, muscle and AT.  All of these 
were studied in this dissertation; however, the focus was AT inflammation. AT 
inflammation has been shown to be one of the hallmarks of obesity and is likely 
the seminal process of metabolic tissue dysfunction systemically. 
 Assessment of gene expression associated with obesity in AT led to the 
identification of inflammatory genes normally associated with macrophages (18, 
19, 22, 24). Increases in AT macrophage number and a pro-inflammatory gene 
expression profile are temporally associated with the development of IR (19, 29). 
Thus, investigating the mediators that initiate and promote macrophage 
recruitment to AT became vital towards understanding a unifying 
mechanism/solution for the metabolic dysregulation in obesity. When the work on 
this dissertation project began, much emphasis in this field was placed on 
identifying factors that could lead to the recruitment of macrophages to AT. With 
the goal of delineating the function of leptin as a chemokine in macrophage 
accumulation into AT, we designed the experiments in Chapter III to test its 
function in vivo. During the second through fourth years of my dissertation, 
several papers were published evaluating the importance of the macrophage 
phenotype as well as other immune cells in AT inflammation (52-54). Using 
CCR2 deficient mice as a positive control for Chapter III, I made the discovery of 
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eosinophils in the AT of mice as well as the role of CCR2/eosinophils in 
regulating the polarization of macrophages and AT inflammatory state (Chapter 
IV). Lastly, with the goal of establishing the role of C5a in macrophage 
accumulation and inflammation in AT, I discovered a novel inflammation-
independent regulation of glucose metabolism by a component of the immune 
system (Chapter V).  
Macrophage Chemotaxis into AT 
Several inflammatory chemokines and chemokine-receptors that could 
play a role in macrophage recruitment have been investigated including: CCR2, 
CCL2, CCL3 and CX3CR1 (30, 35, 38, 41). The initial project of this dissertation 
focused on testing a potential role for the adipokine leptin in this process. Leptin 
was shown by our laboratory to be a potent monocyte chemoattractant in vitro. 
Furthermore, our studies showed that the long form of the LepR was required for 
monocyte chemotaxis towards leptin (43). Additionally, a study by Curat et al. 
showed that leptin was important in upregulating adhesion molecules in the blood 
vessels to promote monocyte diapedesis in AT (103). These findings led many 
investigators to speculate that leptin could play a role in macrophage recruitment 
to AT in vivo (44, 45).  In Chapter III of this dissertation, I showed that leptin 
receptor deficiency in hematopoietic cells does not affect macrophage 
recruitment to AT (36). This is the first published report that actually tested the 
commonly held belief that leptin is involved in macrophage infiltration into AT in 
vivo (21, 44, 45). Furthermore, this study also showed that leptin receptor 
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deficiency does not affect macrophage inflammatory gene expression in vivo or 
in vitro.  
This was a surprising outcome for these studies at that time. However, 
they do not completely rule out that leptin is important in AT inflammation, due to 
the extensive compensation observed in other chemokine disruption 
experiments. However, from the time when these experiments were initiated up 
to now, several papers have been published suggesting that removal of a single 
chemokine receptor has little or no effect on macrophage accumulation in AT 
(32, 38-40). Chapter III not only adds a new chemokine whose disruption does 
not affect macrophage accumulation in AT to this field, but because I used mice 
that lacked both the LepR and CCR2 in their hematopoietic cells, my 
experiments showed that even in the absence of the function of four potent 
monocyte chemokines (leptin, CCL2, CCL7, and CCL8), there is little to no effect 
in the amount of macrophages that accumulate in AT. Collectively the results 
from Chapter III suggest that recruitment of macrophages to AT might not be an 
important factor in controlling the number of these cells found in AT during 
obesity. Furthermore, the turnover of these cells rather than their recruitment in 
AT maybe a more important determinant of the prevalence of macrophages in 
this tissue.  
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Macrophage Polarization and Other Immune Cells 
Macrophages are merely one of the many immune cells that coordinate 
inflammation in AT.  Several other cells have been shown to regulate AT 
inflammation, including eosinophils, which have been implicated in directly 
modulating the phenotype of AT macrophages. Eosinophils in AT were first 
described by Wu et al. who showed that eosinophils are the main producers of 
interleukin 4 (IL-4) in the AT (49). IL4 is a TH2 cytokine that promotes 
macrophage alternative activation; thus, ablation of eosinophils leads to 
decreased M2 macrophages, increased IR and dysregulated AT function (49).  In 
Chapter IV of this dissertation, I also describe the discovery of these cells in the 
AT of mice. More importantly, we were the first to report that eosinophils 
aberrantly accumulate in the AT of CCR2-/- mice, which gave us insight into their 
regulation during obesity as well as their origin. Eosinophils constitute about 10% 
of the total stromal vascular cells in lean wild-type mice; this percentage is 
progressively decreased with increasing obesity, and they are no longer detected 
after 20 weeks of HFD feeding. In CCR2-/- mice they are initially increased with 
obesity; however, similar to the wild type mice, after extended periods of HFD 
feeding they eventually disappear. Eosinophils are localized in the interstitial 
space between adipocytes and not in crown-like structures, as is the case for 
most inflammatory immune cells. Eosinophilia is only detected in the AT and 
peritoneal cavity of CCR2-/- mice, which indicates that their increased numbers is 
likely due to local proliferation and not increased recruitment. In support of this, 
the levels of IL-5, an eosinopoeitic molecule, are closely correlated to the levels 
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of esosinophils in AT. Furthermore, the IL5 expression appears to be restricted to 
the M2 macrophages in AT. These data suggest that although eosinophils 
promote M2 activation in AT, their proliferation is also dependent on M2 
macrophages themselves, in a self-renewing loop. Thus, targeting either cell type 
will lead to the ablation of other cell population.  
Inflammation-Independent Modulation of Glucose Metabolism by the 
Immune System 
Our laboratory is interested in AT-specific mechanisms of immune 
involvement in the pathogenesis of obesity. Along this common interest, I 
designed the AT-centered hypothesis that deficiency of complement factor 5 
would lead to decreased macrophage recruitment and AT inflammation. C5a, 
one of the cleavage products of C5, is known to be a potent chemoattractant for 
macrophages and other immune cells. Additionally, this anaphylatoxin has been 
shown to be one of the most potent inducers of inflammation in all leukeocytes, 
especially macrophages and neutrophils (61). To support my hypothesis, I 
showed that C5 expression was increased in visceral AT with increasing levels of 
obesity.  As presented in Chapter V of this dissertation, using mice with a 
deficiency in C5, we discovered a unique case of inflammation-independent 
regulation of glucose metabolism by a component of the immune system. 
In Chapter V, I showed the fortuitous finding that C5 deficiency directly 
affects glucose metabolism by modulating the expression and processing of the 
insulin receptor. Mice deficient in C5 (C5D) were highly glucose intolerant and 
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insulin resistant on a LFD diet, and HFD exacerbated this phenotype. I showed 
that C5 deficiency led to a small decrease in inflammation in both the liver and 
AT, in part supporting our initial hypothesis. However, despite decreased 
inflammation, C5D mice had dysregulated glucose tolerance and IR. In depth 
studies into the mechanism for glucose intolerance and IR showed a decrease in 
the mRNA expression and protein levels of the insulin receptor in all insulin 
sensitive tissues (liver, AT and muscle). Furthermore, we found a defect in the 
glycosylation of the insulin receptor precursor (Pro-INSR), which is necessary for 
the proper maturation of this receptor, in the liver and AT of the C5D mice. This 
coincided with a severe decrease in insulin signaling in these tissues, as shown 
by decrease AKT phosphorylation post-insulin injection.  
Future Directions 
 Chapter III: the results of this study, as well as that of others that 
investigated the effects of chemokine disruption on AT macrophage 
accumulation (38-41), suggest that active macrophage recruitment to AT is likely 
not an important determinant of the number of macrophages in AT. However, 
recent data from our lab suggest that macrophage turnover is a more important 
factor in controlling macrophage numbers in AT. Future studies from our 
laboratory will investigate how important macrophage apoptosis in AT versus 
their recruitment is in maintaining the levels and activation of macrophages in this 
tissue. We are currently working under the hypothesis that obesity decreases 
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macrophage apoptosis and turnover, while lean AT conserves these processes, 
thus sustaining a lower number of macrophages in their AT. 
 Chapter IV: After the culmination of this work, the mechanism for the 
predominant M2 polarization of macrophages and the increased number of 
eosinophils in CCR2-/- mice remains to be tested. What comes first, M2 
polarization, or increased numbers of eosinophils? Future directions for this 
project include: 1) to test the local proliferation of eosinophils by co-culturing 
eosinophils and M2 macrophages isolated from the peritoneal cavity and AT of 
CCR2-/- mice ex vivo, as well as in vivo. 2) To investigate if the predominant M2 
polarization of macrophages in CCR2-/- mice is due to the presence of higher 
levels of eosinophils or if it is due to different mechanisms. Thus, the higher 
levels of eosinophils are a secondary effect of predominant M2 polarization. I 
hypothesize, that CCR2 deficiency leads to a preferential recruitment of Ly6Clo 
monocytes to AT as opposed to the inflammatory Ly6Chi monocytes, which are 
non-existent in this model. The Ly6Clo monocytes predominantly differentiate into 
M2 macrophages (100), thus leading to increased local proliferation of 
eosinophils due to increased IL-5 production by the M2 macrophages. This 
hypothesis will be tested in vivo by performing adoptive transfer experiments of 
Ly6Clo and Ly6Chi monocyte from transgenic mice with GFP expression under a 
β-actin promoter. 3)  To examine the metabolic effects of the systemic ablation of 
eosinophils during HFD feeding. 4) To test whether pharmacological inhibition of 
CCR2 replicates the observed eosinophilia phenotype in the genetic CCR2-/- 
mice by using a CCR2 antagonist in wild type mice. This will potentially extend 
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the application of our findings into humans and aid in understanding the results of 
clinical trials using these inhibitors. 
Chapter V:  The first unanswered question in this study is to investigate 
whether the observed phenotype is specific to the B10.D2-Hc0 H2d H2-T18c/oSnJ 
mice or if this is found in some of the other 16 mouse lines that can be purchased 
from the Jackson Laboratory that are also complement 5 deficient. Furthermore, 
a gene targeted knockout mouse of Hc could be used to test this phenotype. All 
the mouse models currently available to study C5 deficiency, are not gene 
targeted knockout models, but mice that fail to secrete C5; thus, the lack of 
secretion could be affecting insulin receptor expression indirectly and the lack of 
C5 becomes irrelevant in this context.  
Second, I will test whether C5 deficiency is directly affecting the 
expression and processing of the insulin receptor by performing in vitro 
experiments in hepatocytes and adipocytes. In these experiments, we will treat 
adipocytes and hepatocytes with C5a and also use an antibody to antagonize 
this molecule.  
Third, I could test the hypothesis that C5 deficiency is indirectly affecting 
the expression of the INSR by directly promoting glucose intolerance. C5a has 
been shown to potently induce glucose uptake by immune cells, specifically 
neutrophils and eosinophils (155, 156). This glucose uptake is insulin-
independent; however, similar to insulin, it is transporter-mediated. Interestingly, 
mice with a gene deletion in C5L2 have an identical phenotype to what we 
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observed for the C5D mice in Chapter V (158, 160). C5L2 is one of the receptors 
for C5a that preferentially binds to C5a-desArg, which has been shown to have 
no role in promoting inflammation. The potent inflammatory molecule, C5a, has a 
very short half life and the arginase at its N-terminus is promptly cleaved leading 
to the generation of C5a-desArg, which has no inflammatory effects (61). Thus, 
we are now investigating a potential hypoglycemic function for C5a through 
signaling downstream of the C5L2 receptor in metabolic cell lines. Preliminary 
results show that C5a does in fact promote glucose uptake by a hepatocyte cell 
line in vitro. The data presented in Chapter V together with extensive literature 
research suggest that if found, this role for C5a might in fact be important in 
glucose metabolism.  
Summary 
In summary this dissertation has made important contributions to the field 
of Immunometabolism. As a whole this dissertation has contributed to four main 
areas in this field: chemokine-mediated macrophage recruitment to AT, 
macrophage polarization in AT, analysis/discovery of other immune cells in AT, 
and inflammation-independent modulation of metabolism by the immune system. 
Chapter III tested the intriguing hypothesis of a potential role of leptin signaling in 
hematopoietic cells in moncoyte/macrophage recruitment into AT. Chapter IV led 
to the discovery of eosinophils in AT of WT and CCR2-/- mice. This provided a 
mechanism for the delayed protection of CCR2-/- mice against glucose 
intolerance and IR. Additionally, this chapter elucidated a possible mechanism for 
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the sustainment of an M2-like activation of macrophages in AT during a lean 
state, and the promotion of an M1-like phenotype during obesity. Chapter V of 
this dissertation provided one of the first examples of inflammation-independent 
regulation of glucose metabolism and IR by the immune system. The combined 
findings of these Chapters are shown in Figure 6.1. This dissertation led to the 
identification of specific roles for all of these molecules in either macrophage 
recruitment to AT, macrophage polarization, regulation of other immune cells in 
AT, and inflammation-independent regulation of glucose metabolism. 
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Figure 6.1 Model of contributions of this dissertation to the field of 
obesity, insulin resistance and type 2 diabetes. Adapted from Cipolletta et al. 
(55). 
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